0000086115-17-000131.txt : 20171026 0000086115-17-000131.hdr.sgml : 20171026 20171026120011 ACCESSION NUMBER: 0000086115-17-000131 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171026 DATE AS OF CHANGE: 20171026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAFEGUARD SCIENTIFICS INC CENTRAL INDEX KEY: 0000086115 STANDARD INDUSTRIAL CLASSIFICATION: INVESTORS, NEC [6799] IRS NUMBER: 231609753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-05620 FILM NUMBER: 171155498 BUSINESS ADDRESS: STREET 1: 170 NORTH RADNOR-CHESTER ROAD STREET 2: SUITE 200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 6102930600 MAIL ADDRESS: STREET 1: 170 NORTH RADNOR-CHESTER ROAD STREET 2: SUITE 200 CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: SAFEGUARD INDUSTRIES INC DATE OF NAME CHANGE: 19810525 FORMER COMPANY: FORMER CONFORMED NAME: SAFEGUARD CORP DATE OF NAME CHANGE: 19690521 10-Q 1 sfe-2017xq3.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549      
______________________________________________________________________________________________
FORM 10-Q
(Mark One)
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2017
or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From ____________ to ___________
Commission File Number 1-5620      
______________________________________________________________________________________________
Safeguard Scientifics, Inc.
(Exact name of registrant as specified in its charter)      
______________________________________________________________________________________________
Pennsylvania
   
   
(State or other jurisdiction of
   
23-1609753
incorporation or organization)
   
(I.R.S. Employer ID No.)
   
   
170 North Radnor-Chester Road
   
   
Suite 200
   
   
Radnor, PA
   
19087
(Address of principal executive offices)
   
(Zip Code)
(610) 293-0600
Registrant’s telephone number, including area code      
______________________________________________________________________________________________
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  þ    No  ¨
Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).
Yes  þ    No  ¨
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
   
Large accelerated filer  ¨
Accelerated filer  þ
 
Smaller reporting company  ¨
Non-accelerated filer  ¨

(Do not check if a smaller reporting company)
Emerging growth company  ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ¨    No  þ
Number of shares outstanding as of October 24, 2017
Common Stock 20,412,398
 



SAFEGUARD SCIENTIFICS, INC.
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS
   
PART I – FINANCIAL INFORMATION
   
   
Page
Item 1 – Financial Statements:
   
   
   
   
   
   
   
 
 
   
   
   
   
   
   
   
   
   
   
   
   
PART II – OTHER INFORMATION
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
   


2




SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited - In thousands, except per share data)
   
September 30,
2017
 
December 31, 2016
ASSETS
 
 
   
Current Assets:
   
 
   
Cash and cash equivalents
$
34,317

 
$
22,058

Marketable securities
5,171

 
8,384

Trading securities
3,881

 
—

Prepaid expenses and other current assets
3,691

 
2,109

Total current assets
47,060

 
32,551

Property and equipment, net
1,626

 
1,873

Ownership interests in and advances to partner companies
138,698

 
183,470

Long-term marketable securities
249

 
7,302

Long-term restricted cash equivalents
6,336

 
6,336

Other assets
316

 
296

Total Assets
$
194,285

 
$
231,828

LIABILITIES AND EQUITY
   
 
 
Current Liabilities:
 
 
 
Accounts payable
$
171

 
$
140

Accrued compensation and benefits
2,844

 
3,498

Accrued expenses and other current liabilities
2,495

 
2,223

Convertible senior debentures - current
40,148

 
—

Total current liabilities
45,658

 
5,861

Other long-term liabilities
3,504

 
3,630

Credit facility
44,911

 
—

Convertible senior debentures
—

 
52,560

Total Liabilities
94,073

 
62,051

Commitments and contingencies


 


Equity:
   
 
 
Preferred stock, $0.10 par value; 1,000 shares authorized
—

 
—

Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued at September 30, 2017 and December 31, 2016
2,157

 
2,157

Additional paid-in capital
815,031

 
816,016

Treasury stock, at cost; 1,161 and 1,209 shares at September 30, 2017 and December 31, 2016, respectively
(20,124
)
 
(21,061
)
Accumulated deficit
(696,748
)
 
(626,904
)
Accumulated other comprehensive loss
(104
)
 
(431
)
Total Equity
100,212

 
169,777

Total Liabilities and Equity
$
194,285

 
$
231,828

See Notes to Consolidated Financial Statements.

3


SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited - In thousands, except per share data)
   
   
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
General and administrative expense
$
3,758

 
$
4,687

 
$
13,191

 
$
14,764

Operating loss
(3,758
)
 
(4,687
)
 
(13,191
)
 
(14,764
)
Other loss
(379
)
 
(2,405
)
 
(219
)
 
(1,746
)
Interest income
1,004

 
513

 
2,892

 
1,460

Interest expense
(2,643
)
 
(1,161
)
 
(5,953
)
 
(3,465
)
Equity income (loss)
(12,874
)
 
(16,345
)
 
(53,373
)
 
17,954

Net loss before income taxes
(18,650
)
 
(24,085
)
 
(69,844
)
 
(561
)
Income tax benefit (expense)
—

 
—

 
—

 
—

Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
 
 
 
 
 
 
 
 
Net loss per share:
   

 
   

 
   

 
   

Basic
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
Diluted
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
Weighted average shares used in computing loss per share:
 
 
 
 
 
 
 
Basic
20,455

 
20,387

 
20,416

 
20,390

Diluted
20,455

 
20,387

 
20,416

 
20,390

   
See Notes to Consolidated Financial Statements.
 

4


SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited - In thousands)
 
 
Three months ended September 30,
 
Nine months ended September 30,
 
2017
 
2016
 
2017
 
2016
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Other comprehensive loss:
 
 
 
 
 
 
 
Share of other comprehensive income of equity method investments
274

 
3

 
277

 
13

Reclassification adjustment for sale of equity method investments
—

 
—

 
50

 
—

Total comprehensive loss
$
(18,376
)
 
$
(24,082
)
 
$
(69,517
)
 
$
(548
)
See Notes to Consolidated Financial Statements.


5


SAFEGUARD SCIENTIFICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited – In thousands)
   
   
Nine months ended September 30,
   
2017
 
2016
Cash Flows from Operating Activities:
   
 
   
Net cash used in operating activities
$
(15,515
)
 
$
(14,114
)
Cash Flows from Investing Activities:
   
 
   
Proceeds from sales of and distributions from companies
16,604

 
73,854

Acquisitions of ownership interests in companies
(11,851
)
 
(34,841
)
Advances and loans to companies
(16,933
)
 
(17,741
)
Repayment of advances and loans to companies
—

 
1,741

Increase in marketable securities
—

 
(18,733
)
Decrease in marketable securities
10,268

 
35,386

Capital expenditures
—

 
(73
)
Net cash provided by (used in) investing activities
(1,912
)
 
39,593

Cash Flows from Financing Activities:
   
 
   
Proceeds from credit facility
50,000

 
—

Issuance costs of credit facility
(5,696
)
 
—

Repurchase of convertible senior debentures
(14,455
)
 
—

Issuance of Company common stock, net
12

 
5

Tax withholdings related to equity-based awards
(175
)
 
(437
)
Repurchase of Company common stock
—

 
(5,389
)
Net cash provided by (used in) financing activities
29,686

 
(5,821
)
Net change in cash, cash equivalents and restricted cash equivalents
12,259

 
19,658

Cash, cash equivalents and restricted cash equivalents at beginning of period
28,394

 
32,838

Cash, cash equivalents and restricted cash equivalents at end of period
$
40,653

 
$
52,496

See Notes to Consolidated Financial Statements.


6


SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
(Unaudited – In thousands)
   
 
 
 
 
 
Accumulated Other Comprehensive Loss
 
 
 
 
 
 
 
 
 
 
   
 
 
Accumulated
Deficit
 
 
Common Stock
 
Additional
Paid-in
Capital
 
Treasury Stock
   
Total
 
 
Shares
 
Amount
 
 
Shares
 
Amount
Balance - December 31, 2016
$
169,777

 
$
(626,904
)
 
$
(431
)
 
21,573

 
$
2,157

 
$
816,016

 
1,209

 
$
(21,061
)
Net loss
(69,844
)
 
(69,844
)
 
—

 
—

 
—

 
—

 
—

 
—

Stock options exercised, net of tax withholdings
12

 
—

 
—

 
—

 
—

 
(48
)
 
(4
)
 
60

Issuance of restricted stock, net of tax withholdings
(40
)
 
—

 
—

 
—

 
—

 
(917
)
 
(44
)
 
877

Stock-based compensation expense
806

 
—

 
—

 
—

 
—

 
806

 
—

 
—

Repurchase of convertible senior debentures
(826
)
 
—

 
—

 
—

 
—

 
(826
)
 
—

 
—

Other comprehensive income
327

 
—

 
327

 
—

 
—

 
—

 
—

 
—

Balance - September 30, 2017
$
100,212

 
$
(696,748
)
 
$
(104
)
 
21,573

 
$
2,157

 
$
815,031

 
1,161

 
$
(20,124
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Notes to Consolidated Financial Statements.


7


SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. General
The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2016 Annual Report on Form 10-K.
Liquidity
As of September 30, 2017, the Company had $34.3 million of cash and cash equivalents and $5.4 million of marketable securities for a total of $39.7 million. As of September 30, 2017, the Company had $41.0 million of principal outstanding on its convertible senior notes, which the Company anticipates repaying or refinancing by the maturity date of May 15, 2018.
In May 2017, the Company entered into a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). As of September 30, 2017, the Company had $50.0 million of principal outstanding on the Credit Facility due in May 2020. The Credit Facility requires the Company to maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash, of at least 1.75x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of the Company’s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold, of at least $350 million; and (iv) certain diversification requirements and concentration limits with respect to the Company’s capital deployments to its partner companies. As of the date these consolidated financial statements were issued, the Company was in compliance with all of these covenants.
The Company funds its operations with cash and marketable securities on hand as well as proceeds from the sales of its interest in its partner companies. Due to the nature of the mergers and acquisitions market, and the developmental cycle of companies like the Company’s partner companies, the Company’s ability to generate specific amounts of liquidity from sales of its partner company interests in any given period of time cannot be assured. Accordingly, the forecasts which the Company utilizes for projecting future compliance with covenants related to its Credit Facility include significantly discounted probability-weighted proceeds from the sales of its interests in its partner companies. Based on these forecasts, management believes the Company will continue to remain in compliance with all of its debt covenants. Management's plans to remain in compliance with these covenants include selling certain of its partner company interests in the ordinary course of its business and limiting capital deployments to new and existing partner companies.
Non-compliance with any of the covenants would constitute an event of default under the Credit Facility, and the Lender could choose to accelerate the maturity of the indebtedness. If the Lender were to accelerate the maturity of the indebtedness, the Company may not have sufficient immediate liquidity to repay the entire balance of its outstanding borrowings and other obligations under the Credit Facility. Should the Company not be in compliance with any of its debt covenants and be unable to obtain waivers for such events of default, management would pursue one of a number of potential alternatives to satisfy the obligations, including completing an equity offering or obtaining a new debt facility to refinance its existing debt.
Significant Accounting Policies
Restricted Cash Equivalents
Restricted cash equivalents consist of certificates of deposit with various maturity dates. Amounts included in restricted cash equivalents represent those required to be set aside by a contractual agreement with a bank as collateral for a letter of credit. The restriction on the cash will lapse when the related letter of credit is terminated or expires. The letter of credit is scheduled to expire on March 31, 2019. The following table provides a reconciliation of cash, cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:

8


 
September 30, 2017
 
December 31, 2016
 
(Unaudited - In thousands)
Cash and cash equivalents
$
34,317

 
$
22,058

Long-term restricted cash equivalents
6,336

 
6,336

Total cash, cash equivalents and restricted cash equivalents
$
40,653

 
$
28,394


Recent Accounting Pronouncements
Evaluation of Accounting Standards Update No. 2014-09
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 and related subsequent amendments outline a single comprehensive model to use to account for revenue arising from contracts with customers and supersede most current revenue recognition guidance. For public companies, the guidance is effective for annual periods beginning after December 15, 2017 and any interim periods that fall within that reporting period. For nonpublic companies, the guidance is effective for annual periods beginning after December 15, 2018 and interim periods within annual periods beginning after December 15, 2019 with early adoption permitted. As the new standard will supersede most existing revenue guidance, it could impact revenue and cost recognition for partner companies. Any change in revenue or cost recognition for partner companies could affect the Company's recognition of its share of the results of its equity method partner companies. The Company has been closely monitoring the FASB and SEC activity related to the new standard.  On July 20, 2017, the SEC staff observer at the FASB’s Emerging Issues Task Force ("EITF") meeting announced that the SEC staff will not object if a private company equity method investee meeting the definition of a public business entity that otherwise would not meet the definition of a public business entity except for the inclusion of its financial statements or financial information in another entity’s filings with the SEC, uses private company adoption dates for the new revenue standard.  As a result, the Company anticipates that its private, calendar year partner companies will adopt the new revenue standard for the year ending December 31, 2019.  The impact of adoption of the new revenue standard will be reflected in the Company’s financial results for the interim and annual reporting periods beginning in 2020 on a one quarter-lag basis.

2. Ownership Interests in and Advances to Partner Companies
The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies.   
   
September 30, 2017
 
December 31, 2016
   
(Unaudited - In thousands)
Equity Method:
   
 
 
Partner companies
$
113,869

 
$
154,219

Private equity funds
444

 
447

   
114,313

 
154,666

Cost Method:
   
 
 
Other holdings
2,762

 
2,112

Private equity funds
1,334

 
1,550

   
4,096

 
3,662

Advances to partner companies
20,289

 
25,142

   
$
138,698

 
$
183,470

In August 2017, Good Start Genetics, Inc. was acquired by Invitae Corporation ("Invitae"). The Company received 414,237 shares of Invitae common stock worth $4.3 million on the closing date in connection with the transaction, excluding 137,125 shares of Invitae common stock worth $1.4 million on the closing date which will be held in escrow until August 2018. The Company recognized a gain of $4.3 million on the transaction, which is included in Equity income (loss) in the Consolidated Statements of Operations for the three and nine months ended September 30, 2017. The Invitae shares are classified as Trading securities and recorded at fair value on the Consolidated Balance Sheet at September 30, 2017.
In March 2017, the Company sold its interest in partner company Nexxt, Inc., formerly Beyond.com, back to Nexxt, Inc. for $26.0 million. The Company received $15.5 million in cash and a three-year, $10.5 million note for the balance due, which accrues interest at a rate of 9.5% per annum. The receipt of the $15.5 million in cash resulted in a gain of $0.1 million which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.

9
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The $10.5 million note is fully reserved and has a carrying value of zero as of September 30, 2017. A gain will be recorded when the note is repaid. Interest is payable annually and interest income is recorded as earned throughout the year.
In the second quarter of 2017, the Company recognized an impairment charge of $3.6 million related to Spongecell, Inc. which is reflected in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The impairment was based on the value at which the Company expects Spongecell to raise its next financing round.
In the first and second quarters of 2017, the Company recognized impairment charges of $2.7 million and $2.2 million, respectively, related to Pneuron, Inc. which is reflected in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The impairments were due to a decline in revenue and an inability to attract third party investors or acquirers. Pneuron has ceased business operations and the adjusted carrying value of the Company's interest in Pneuron is $0.0 million at September 30, 2017.
In April 2016, Putney, Inc. was acquired by Dechra Pharmaceuticals Plc. The Company received $58.6 million in cash proceeds in connection with the transaction. In April 2017, the Company received an additional $0.7 million in connection with the expiration of the final escrow period resulting in a gain of $0.7 million which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.
In July 2015, Quantia, Inc. was acquired by Physicians Interactive. The Company received $7.8 million in initial cash proceeds in connection with the transaction in July 2015 and $0.6 million in connection with the expiration of the initial escrow period in July 2016. In January 2017, the Company received an additional $0.6 million in connection with the expiration of the final escrow period resulting in a gain of $0.6 million which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.

3. Acquisitions of Ownership Interests in Partner Companies
In September, August, March and February 2017, the Company funded an aggregate of $4.9 million of convertible bridge loans to InfoBionic, Inc. The Company had previously deployed an aggregate of $14.5 million in InfoBionic. InfoBionic is an emerging digital health company focused on creating patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. The Company accounts for its interest in InfoBionic under the equity method.
In September, July and June 2017, the Company funded an aggregate of $1.6 million of convertible bridge loans to Cask Data, Inc. The Company had previously deployed an aggregate of $11.0 million in Cask Data. Cask Data makes building and running big data solutions on-premises or in the cloud easy with Cask Data Application Platform. The Company accounts for its interest in Cask Data under the equity method.
In September 2017, the Company deployed $2.5 million into meQuilibrium. The Company had previously deployed an aggregate of $8.0 million in meQuilibrium. meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being. The Company accounts for its interest in meQuilibrium under the equity method.
In August 2017, the Company funded $0.3 million of convertible bridge loans to Hoopla Software, Inc. The Company had previously deployed an aggregate of $4.8 million in Hoopla Software. Hoopla Software provides cloud-based software that helps sales organizations inspire and motivate sales team performance. The Company accounts for its interest in Hoopla Software under the equity method.
In August, June and February 2017, the Company funded an aggregate of $1.5 million of convertible loans to NovaSom, Inc. The Company had previously deployed an aggregate of $22.1 million in NovaSom. NovaSom is a medical device company focused on obstructive sleep apnea, specifically home testing with its FDA-cleared wireless device called AccuSom® home sleep test. The Company accounts for its interest in NovaSom under the equity method.
In July 2017, the Company deployed $1.8 million into QuanticMind, Inc. The Company had previously deployed an aggregate of $9.7 million in QuanticMind. QuanticMind delivers the most intelligent, scalable and fastest platform for maximizing digital marketing performance, including paid search and social, for enterprises. The Company accounts for its interest in QuanticMind under the equity method.
In June and April 2017, the Company funded an aggregate of $3.0 million of a convertible bridge loan to Sonobi, Inc. The Company had previously deployed $5.4 million in Sonobi. Sonobi is an advertising technology developer that designs advertising tools and solutions for the industry's leading media, publishers, brand advertisers, media agencies, DSPs, and media technology providers. The Company accounts for its interest in Sonobi under the equity method.
In June and January 2017, the Company funded an aggregate of $2.0 million of convertible bridge loans to WebLinc, Inc. The Company had previously deployed an aggregate of $12.0 million in WebLinc. WebLinc is a commerce platform and services provider for fast growing online retailers. The Company accounts for its interest in WebLinc under the equity method.

10
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


In June 2017, the Company funded $1.8 million of a convertible bridge loan to Good Start Genetics, Inc. The Company had previously deployed an aggregate of $17.2 million in Good Start Genetics. Good Start Genetics was acquired by Invitae Corporation in August 2017.
In May 2017, the Company deployed $2.1 million into Trice Medical, Inc. The Company had previously deployed an aggregate of $8.0 million in Trice Medical. Trice Medical is a diagnostics company focused on micro invasive technologies. The Company accounts for its interest in Trice Medical under the equity method.
In April 2017, the Company deployed $1.5 million into Aktana, Inc. The Company had previously deployed an aggregate of $8.2 million in Aktana. Aktana leverages big data and machine learning to enable pharmaceutical brands to dynamically optimize their strategy and enhance sales execution. The Company accounts for its interest in Aktana under the equity method.
In March and January 2017, the Company deployed an aggregate of $2.0 million into CloudMine, Inc. The Company had previously deployed an aggregate of $5.5 million in CloudMine. CloudMine empowers payers, providers, and pharmaceutical organizations to mobilize patient information by building robust applications and driving actionable insights. The Company accounts for its interest in CloudMine under the equity method.
In March 2017, the Company funded $0.2 million of a bridge loan to Lumesis, Inc. The Company had previously deployed an aggregate of $6.2 million in Lumesis. Lumesis is a financial technology company focused on providing business efficiency, regulatory and data solutions to the municipal bond marketplace. The Company accounts for its interest in Lumesis under the equity method.
In January 2017, the Company deployed $2.4 million into Full Measure Education, Inc. The Company had previously deployed an aggregate of $8.6 million in Full Measure. Full Measure designs next-generation, mobile-first technologies for colleges throughout the United States. The Company accounts for its interest in Full Measure under the equity method.
In January 2017, the Company funded $0.3 million of a convertible bridge loan to Aventura, Inc. to fund wind-down activities. The Company had previously deployed an aggregate of $6.2 million in Aventura. The adjusted carrying value of the Company's interest in Aventura was $0.0 million at September 30, 2017. The Company accounted for its interest in Aventura under the equity method.

4. Fair Value Measurements
The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial instruments recorded at fair value on the Company’s Consolidated Balance Sheets are categorized as follows:
Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Include other inputs that are directly or indirectly observable in the marketplace.
Level 3—Unobservable inputs which are supported by little or no market activity.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016:
   
Carrying
Value
 
Fair Value Measurement at September 30, 2017
   
Level 1
 
Level 2
 
Level 3
 
(Unaudited - In thousands)
Cash and cash equivalents
$
34,317

 
$
34,317

 
$
—

 
$
—

Long-term restricted cash equivalents

6,336

 
6,336

 
—

 
—

Trading securities
3,881

 
3,881

 
—

 
—

Marketable securities—held-to-maturity:
   
 
   
 
   
 
   
Certificates of deposit
$
5,420

 
$
5,420

 
$
—

 
$
—

 Total marketable securities
$
5,420

 
$
5,420

 
$
—

 
$
—


11
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


 
Carrying
Value
 
Fair Value Measurement at December 31, 2016
   
Level 1
 
Level 2
 
Level 3
 
(Unaudited - In thousands)
Cash and cash equivalents
$
22,058

 
$
22,058

 
$
—

 
$
—

Long-term restricted cash equivalents
6,336

 
6,336

 
—

 
—

Marketable securities—held-to-maturity:
   
 
 
 
 
 
 
Certificates of deposit
$
15,686

 
$
15,686

 
$
—

 
$
—

 Total marketable securities
$
15,686

 
$
15,686

 
$
—

 
$
—

As of September 30, 2017, $5.2 million of marketable securities had contractual maturities which were less than one year and $0.2 million of marketable securities had contractual maturities greater than one year. Certificates of deposit are classified as held-to-maturity securities carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1 inputs under the fair value hierarchy. Trading securities consist of 414,237 shares of Invitae Corporation common shares obtained in connection with the sale of Good Start Genetics. The trading securities are carried at fair value based on the closing stock price on the last trading day of the reporting period.

5. Credit Facility and Convertible Debentures
Credit Facility
In May 2017, the Company entered into a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). At closing, the Company borrowed $50.0 million, which resulted in net proceeds of $44.3 million after closing fees to the Lender and other third parties. The Credit Facility has a three-year term with a scheduled maturity of May 11, 2020 and bears interest at a rate of either: (A) LIBOR plus 8.5% (subject to a LIBOR floor of 1%), payable on the last day of the one, two or three month interest period applicable to the LIBOR rate advance, or (B) 7.5% plus the greater of: 2%; the Federal Funds Rate plus 0.5%; LIBOR plus 1%; or the U.S. Prime Rate, payable monthly in arrears. The Credit Facility is not amortized and interest payable under the Credit Facility will reflect at least $50 million as being drawn and outstanding at all times during the term. The Credit Facility also includes an unused line fee equal to 0.75% per annum of the average unused portion of the Credit Facility and a loan service fee, both paid quarterly. The Credit Facility is secured by all of the Company's assets in accordance with the terms of the Credit Facility.
The Credit Facility requires the Company to maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash of at least 1.75x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of the Company’s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold of at least $350 million; and (iv) certain diversification requirements and concentration limits with respect to the Company’s capital deployments to its partner companies. Subject to customary exclusions, the Lender has the right to have one observer representative attend meetings of the Company's Board of Directors.
The Credit Facility provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, nonpayment of principal or interest; non-compliance with debt covenants; defaults in, or failure to pay, certain other indebtedness; the rendering of judgments to pay certain amounts of money; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is not cured within the time periods specified (if any), the Lender may declare the outstanding amount under the Credit Facility to be immediately due and payable.
At September 30, 2017, the principal amount outstanding under the Credit Facility was $50.0 million, the unamortized discount and debt issuance costs were $5.1 million and the net carrying value of the credit facility was $44.9 million. The Company is amortizing the excess of the principal amount of the Credit Facility over its carrying value over the three-year term as additional interest expense using the effective interest method and recorded $0.4 million and $0.6 million of such expense for the three and nine months ended September 30, 2017. The effective interest rate on the Credit Facility is 14.5%.
Convertible Debentures
In November 2012, the Company issued $55.0 million principal amount of its 5.25% convertible senior debentures due on May 15, 2018 (the “2018 Debentures”). The 2018 Debentures may be settled in cash or partially in cash upon conversion. Accordingly, the Company separately accounts for the liability and equity components of the 2018 Debentures. The carrying amount of the liability component was determined at the transaction date by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component represented by the embedded conversion option was determined by deducting the fair value of the liability component from the initial proceeds of the 2018 Debentures as a whole.

12
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


In July and June 2017, the Company repurchased on the open market, and retired, an aggregate of $14.0 million face value of the 2018 Debentures at a cost of $14.5 million, including transaction fees. In connection with the repurchase of these 2018 Debentures, the Company recognized a $0.8 million reduction in equity which is included in Accumulated Paid-In Capital in the Consolidated Balance Sheet as of September 30, 2017 and a $29 thousand loss on extinguishment of the liability which is included in Other loss in the Consolidated Statements of Operations for the nine months ended September 30, 2017.
At September 30, 2017, the carrying amount of the equity component was $5.7 million, the principal amount of the liability component was $41.0 million, the unamortized discount and debt issuance costs were $0.9 million and the net carrying value of the liability component was $40.1 million. The Company is amortizing the excess of the face value of the 2018 Debentures over their carrying value over their term as additional interest expense using the effective interest method and recorded $0.4 million of such expense for the three months ended September 30, 2017 and 2016, and $1.6 million and $1.2 million for the nine months ended September 30, 2017 and 2016, respectively. The effective interest rate on the 2018 Debentures is 8.7%. At September 30, 2017, the fair value of the $41.0 million outstanding 2018 Debentures was approximately $42.2 million, based on the midpoint of the bid and ask prices as of such date. The Company anticipates repaying or refinancing the outstanding 2018 Debentures by the maturity date of May 15, 2018.

6. Stock-Based Compensation
Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:   
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
 
(Unaudited - In thousands)
General and administrative expense
$
560

 
$
604

 
$
806

 
$
1,879

   
$
560

 
$
604

 
$
806

 
$
1,879

The fair value of the Company’s option awards to employees was estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate was based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected term of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility measured using weekly price observations of the Company’s common stock for a period equal to the stock option’s expected term.
At September 30, 2017, the Company had outstanding options that vest based on two different types of vesting schedules:
1)
performance-based;
2)
service-based.
Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company’s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. During the nine months ended September 30, 2017 and 2016, the Company did not issue any performance-based options to employees. During the nine months ended September 30, 2017 and 2016, 0 thousand and 4 thousand performance-based options vested, respectively. During the nine months ended September 30, 2017 and 2016, 8 thousand and 35 thousand performance-based options were canceled or forfeited. The Company recorded compensation expense related to performance-based options of $0.0 million for the three months ended September 30, 2017 and a reduction in compensation expense of $0.2 million for the nine months ended September 30, 2017. The Company recorded compensation expense related to performance-based options of $0.0 million and $0.2 million for the three and nine months ended September 30, 2016, respectively. The maximum number of unvested options at September 30, 2017 attainable under these grants was 284 thousand shares.
Service-based options generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based options is the period over which the award vests. During the nine months ended September 30, 2017 and 2016, the Company issued 0 thousand and 12 thousand service-based options, respectively, to employees. During the nine months ended September 30, 2017 and 2016, 78 thousand and 12 thousand service-based options, respectively, were canceled or forfeited. The Company recorded compensation expense related to service-based options of $0.0 million and $0.1 million

13
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


for the three and nine months ended September 30, 2017, respectively. The Company recorded compensation expense related to service-based options of $0.1 million and $0.1 million for the three and nine months ended September 30, 2016, respectively.
Performance-based stock units vest based on achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies, as described above related to performance-based awards. Performance-based stock units represent the right to receive shares of the Company’s common stock, on a one-for-one basis. During the nine months ended September 30, 2017 and 2016, the Company did not issue any performance-based stock units to employees and no performance-based stock units vested. During the nine months ended September 30, 2017 and 2016, 6 thousand and 0 thousand performance-based stock units were canceled or forfeited. Under the terms of the 2016, 2015 and 2014 performance-based awards, once performance-based stock units are fully vested, participants are entitled to receive cash payments based on their initial performance grant values as target capital returns are exceeded. At September 30, 2017, the liability associated with such potential cash payments was $0.0 million.
During the nine months ended September 30, 2017 and 2016, the Company issued 50 thousand and 43 thousand deferred stock units, respectively, to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in lieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of employment or service, death or permanent disability.
During the nine months ended September 30, 2017 and 2016, the Company issued 7 thousand and 0 thousand restricted stock awards, respectively, and 3 thousand and 1 thousand restricted stock awards were canceled or forfeited, respectively.
Total compensation expense for performance-based stock units, deferred stock units, and restricted stock was $0.5 million and $0.5 million for the three months ended September 30, 2017 and 2016, respectively, and $1.0 million and $1.5 million for the nine months ended September 30, 2017 and 2016, respectively.
7. Income Taxes
The Company’s consolidated income tax benefit (expense) was $0.0 million for the three and nine months ended September 30, 2017 and 2016. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in the three and nine months ended September 30, 2017 was offset by changes in the valuation allowance. The tax expense that would have been recognized in the three and nine months ended September 30, 2016 was offset by changes in the valuation allowance. During the nine months ended September 30, 2017, the Company had no material changes in uncertain tax positions.

8. Net Income (Loss) Per Share
The calculations of net income (loss) per share were as follows:
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
 
(Unaudited - In thousands, except per share data)
Basic:
   
 
   
 
   
 
   
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Weighted average common shares outstanding
20,455

 
20,387

 
20,416

 
20,390

Net loss per share
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
 
 
 
 
 
 
 
 
Diluted:
 
 
 
 
 
 
 
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Weighted average common shares outstanding
20,455

 
20,387

 
20,416

 
20,390

Net loss for dilutive share computation
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
 
 
 
 
 
 
 
 
Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

14
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


If a consolidated or equity method partner company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the partner company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.
Diluted earnings per share for the three and nine months ended September 30, 2017 and 2016 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:
•
At September 30, 2017 and 2016, options to purchase 0.6 million and 0.7 million shares of common stock, respectively, at prices ranging from $9.83 to $19.95 and $9.83 to $19.95, respectively, were excluded from the calculations.
•
At September 30, 2017 and 2016, unvested restricted stock, performance-based stock units and DSUs convertible into 0.9 million and 0.6 million shares of stock, respectively, were excluded from the calculations.
•
At September 30, 2017 and 2016, 2.3 million and 3.0 million shares of common stock representing the effect of the assumed conversion of the 2018 Debentures, were excluded from the calculations.
9. Segment Reporting
The Company operates as one operating segment based upon the similar nature of its technology-driven partner companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. As of September 30, 2017, the Company held interests in 26 non-consolidated partner companies. The Company’s active partner companies were as follows as of September 30, 2017:
Partner Company
Safeguard Primary Ownership as of September 30, 2017
 
Accounting Method
AdvantEdge Healthcare Solutions, Inc.
40.1%
 
Equity
Aktana, Inc.
24.5%
 
Equity
Apprenda, Inc.
29.4%
 
Equity
Brickwork
20.3%
 
Equity
Cask Data, Inc.
31.3%
 
Equity
CloudMine, Inc.
47.4%
 
Equity
Clutch Holdings, Inc.
42.7%
 
Equity
Full Measure Education, Inc.
42.3%
 
Equity
Hoopla Software, Inc.
25.5%
 
Equity
InfoBionic, Inc.
39.5%
 
Equity
Lumesis, Inc.
43.8%
 
Equity
MediaMath, Inc.
20.4%
 
Equity
meQuilibrium
37.0%
 
Equity
Moxe Health Corporation
32.4%
 
Equity
NovaSom, Inc.
31.7%
 
Equity
Prognos (fka Medivo, Inc.)
35.2%
 
Equity
Propeller Health, Inc.
24.0%
 
Equity
QuanticMind, Inc.
24.7%
 
Equity
Sonobi, Inc.
21.6%
 
Equity
Spongecell, Inc.
23.0%
 
Equity
Syapse, Inc.
26.0%
 
Equity
T-REX Group, Inc.
21.3%
 
Equity
Transactis, Inc.
23.8%
 
Equity
Trice Medical, Inc.
24.9%
 
Equity
WebLinc, Inc.
38.0%
 
Equity
Zipnosis, Inc.
25.4%
 
Equity
 As of September 30, 2017 and December 31, 2016, all of the Company’s assets were located in the United States.

15
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


10. Commitments and Contingencies
The Company and its partner companies are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its partner companies. The Company records costs associated with legal fees as such services are rendered.
The Company had outstanding guarantees of $3.8 million at September 30, 2017 which related to one of the Company's private equity holdings.
The Company is required to return a portion or all the distributions it received as a general partner of a private equity fund for further distribution to such fund's limited partners (“clawback”). The Company’s ownership in the fund is 19%. The clawback liability is joint and several, such that the Company may be required to fund the clawback for other general partners should they default. The Company believes its potential liability due to the possibility of default by other general partners is remote. The Company was notified by the fund's manager that the fund is being dissolved and $1.0 million of the Company's clawback liability was paid in the first quarter of 2017. The maximum additional clawback liability is $0.3 million which was reflected in Other long-term liabilities on the Consolidated Balance Sheet at September 30, 2017.
 
In October 2001, the Company entered into an agreement with a former Chairman and Chief Executive Officer of the Company, to provide for annual payments of $0.65 million per year and certain health care and other benefits for life. The related current liability of $0.8 million was included in Accrued expenses and other current liabilities and the long-term portion of $1.8 million was included in Other long-term liabilities on the Consolidated Balance Sheet at September 30, 2017.
The Company provided a $6.3 million letter of credit that is scheduled to expire on March 31, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters as required in connection with the sale of CompuCom Systems in 2004. The letter of credit is secured by cash which is classified as Long-term restricted cash equivalents on the Consolidated Balance Sheet.
The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under the agreements was approximately $3.0 million at September 30, 2017.
In June 2011, the Company's former partner company, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH recently entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.

11. Equity
In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the nine months ended September 30, 2016, the Company repurchased 0.4 million shares at an aggregate cost of $5.4 million with $14.6 million remaining for repurchase under the existing authorization.

16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Concerning Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard” or “we”), the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts. These statements include, in particular, statements about our plans, strategies and prospects. For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our forward-looking statements are subject to risks and uncertainties. Factors that could cause actual results to differ materially, include, among others, our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, our ability to execute our strategy, market valuations in sectors in which our partner companies operate, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies and their performance, including the fact that most of our partner companies have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's partner companies operate, compliance with government regulation and legal liabilities, all of which are discussed in Item 1A. “Risk Factors” in Safeguard's Annual Report on Form 10-K and updated, as applicable, in “Factors that May Affect Future Results” and Item 1A. “Risk Factors” below. Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur.
Business Overview
Safeguard’s charter is to be a nationally recognized leader with respect to entrepreneurship and innovation. Our vision is to provide capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Throughout this document, we use the term “partner company” to generally refer to those companies in which we have an equity interest and in which we are actively involved, influencing development through board representation and management support, in addition to the influence we exert through our equity ownership. From time to time, in addition to these partner companies, we also hold relatively small equity interests in other enterprises where we do not exert significant influence and do not participate in management activities. In some cases, these interests relate to former partner companies and in some cases these interests relate to entities which may later become partner companies.

Safeguard targets technology-driven businesses in healthcare, financial services and digital media that are capitalizing on the next wave of enabling technologies with a particular focus, at present, on the Internet of Everything, enhanced security and predictive analytics. We strive to create long-term value for our shareholders by helping our partner companies to increase their market penetration, grow revenue and improve cash flow. Safeguard typically deploys between $5 million and $15 million of initial capital and $5 million to $10 million of follow-on funding with a total anticipated deployment of up to $25 million in a company. We will occasionally provide certain early-stage seed round financings in amounts generally up to $1 million to promising young companies with the goal to provide more capital once certain development milestones are achieved.
 


17

Results of Operations
We operate as one operating segment based upon the similar nature of our technology-driven partner companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.
There is intense competition in the markets in which our partner companies operate. Additionally, the markets in which these companies operate are characterized by rapidly changing technology, evolving industry standards, frequent introduction of new products and services, shifting distribution channels, evolving government regulation, frequently changing intellectual property landscapes and changing customer demands. Their future success depends on each company’s ability to execute its business plan and to adapt to its respective rapidly changing market.
As previously stated, throughout this document, we use the term “partner company” to generally refer to those companies in which we have an economic interest and in which we are actively involved influencing development, usually through board representation in addition to our equity ownership.
The following listing of our partner companies includes only entities which were considered partner companies as of September 30, 2017. Certain entities which may have been partner companies in previous periods are omitted if, as of September 30, 2017, they had been sold or are no longer considered a partner company.
 
Safeguard Primary Ownership as of September 30,
 
Partner Company
2017
 
2016
Accounting Method
AdvantEdge Healthcare Solutions, Inc.
40.1%
 
40.1%
Equity
Aktana, Inc.
24.5%
 
23.4%
Equity
Apprenda, Inc.
29.4%
 
29.5%
Equity
Brickwork
20.3%
 
NA
Equity
Cask Data, Inc.
31.3%
 
31.3%
Equity
CloudMine, Inc.
47.4%
 
30.1%
Equity
Clutch Holdings, Inc.
42.7%
 
45.0%
Equity
Full Measure Education, Inc.
42.3%
 
36.0%
Equity
Hoopla Software, Inc.
25.5%
 
25.5%
Equity
InfoBionic, Inc.
39.5%
 
40.5%
Equity
Lumesis, Inc.
43.8%
 
44.1%
Equity
MediaMath, Inc.
20.4%
 
20.5%
Equity
meQuilibrium
37.0%
 
31.5%
Equity
Moxe Health Corporation
32.4%
 
32.6%
Equity
NovaSom, Inc.
31.7%
 
31.7%
Equity
Prognos (fka Medivo, Inc.)
35.2%
 
35.3%
Equity
Propeller Health, Inc.
24.0%
 
24.4%
Equity
QuanticMind, Inc.
24.7%
 
23.5%
Equity
Sonobi, Inc.
21.6%
 
21.6%
Equity
Spongecell, Inc.
23.0%
 
23.0%
Equity
Syapse, Inc.
26.0%
 
25.8%
Equity
T-REX Group, Inc.
21.3%
 
NA
Equity
Transactis, Inc.
23.8%
 
24.2%
Equity
Trice Medical, Inc.
24.9%
 
27.7%
Equity
WebLinc, Inc.
38.0%
 
38.0%
Equity
Zipnosis, Inc.
25.4%
 
26.2%
Equity


18

Three months ended September 30, 2017 versus the three months ended September 30, 2016
   
Three months ended September 30,
   
2017
 
2016
 
Variance
 
(In thousands)
General and administrative expense
$
(3,758
)
 
$
(4,687
)
 
$
929

Other loss
(379
)
 
(2,405
)
 
2,026

Interest income
1,004

 
513

 
491

Interest expense
(2,643
)
 
(1,161
)
 
(1,482
)
Equity income (loss)
(12,874
)
 
(16,345
)
 
3,471

 
$
(18,650
)
 
$
(24,085
)
 
$
5,435

General and Administrative Expense. Our general and administrative expenses consist primarily of employee compensation, insurance, travel-related costs, depreciation, office rent and professional services such as consulting, legal, and accounting. General and administrative expense also includes stock-based compensation expense which consists primarily of expense related to grants of stock options, restricted stock and deferred stock units to our employees and directors. General and administrative expense decreased $0.9 million for the three months ended September 30, 2017 compared to the prior year period due to a decrease of $0.7 million in employee costs and a decrease of $0.1 million in professional fees.
Other Loss. Other loss decreased $2.0 million for the three months ended September 30, 2017 compared to the prior year period. Other loss for the three months ended September 30, 2017 primarily reflected a $0.4 million decrease in the fair value of shares of Invitae Corporation common stock obtained in connection with the sale of Good Start Genetics in August 2017. Other loss for the three months ended September 30, 2016 reflected a $2.4 million impairment related to our Penn Mezzanine debt and equity participations.
Interest Income. Interest income includes all interest earned on available cash and marketable security balances as well as interest earned on notes receivable from our partner companies. The increase of $0.5 million for the three months ended September 30, 2017 compared to the prior year period was primarily attributable to higher average notes receivable from our partner companies.
Interest Expense. Interest expense is primarily related to our credit facility and convertible senior debentures.  The increase of $1.5 million for the three months ended September 30, 2017 compared to the prior year period was primarily attributable to $1.7 million of interest expense related to borrowings under the new credit facility we entered into in May 2017, partially offset by a $0.2 million decrease in interest expense due to the repurchase, in aggregate, of $14.0 million face value of convertible senior debentures in June and July 2017.
Equity Loss. Equity loss fluctuates with the number of partner companies accounted for under the equity method, our voting ownership percentage in these partner companies and the net results of operations of these partner companies. We recognize our share of income or losses to the extent we have cost basis in the partner company or outstanding commitments or guarantees. Certain amounts recorded to reflect our share of the income or losses of our partner companies accounted for under the equity method are based on estimates and on unaudited results of operations of those partner companies and may require adjustments in the future when audits of these entities are made final. We report our share of the results of our equity method partner companies on a one quarter lag basis.
Equity loss decreased $3.4 million for the three months ended September 30, 2017 compared to the prior year period. The components of equity loss for the three months ended September 30, 2017 and 2016 were as follows:
Three months ended September 30, 2017:
 
Gain on sale of Good Start Genetics
$
4,250

Unrealized dilution loss on the decrease of our percentage ownership in partner companies
(77
)
Loss on impairment of Pneuron
(206
)
Share of loss of our equity method partner companies
(16,841
)
 
$
(12,874
)

19

Three months ended September 30, 2016:
 
Loss on impairment of Aventura
$
(1,000
)
Gain on proceeds received from escrow related to sale of Quantia
600

Gain on additional proceeds received on the sale of Putney
430

Unrealized dilution gain on the decrease of our percentage ownership in partner companies
365

Share of loss of our equity method partner companies
(16,740
)
 
$
(16,345
)
The change in our share of equity loss of our equity method partner companies for the three months ended September 30, 2017 compared to the prior year period was primarily due to an increase in losses associated with those partner companies.
Nine months ended September 30, 2017 versus the nine months ended September 30, 2016
   
Nine months ended September 30,
   
2017
 
2016
 
Variance
 
(In thousands)
General and administrative expense
$
(13,191
)
 
$
(14,764
)
 
$
1,573

Other loss
(219
)
 
(1,746
)
 
1,527

Interest income
2,892

 
1,460

 
1,432

Interest expense
(5,953
)
 
(3,465
)
 
(2,488
)
Equity income (loss)
(53,373
)
 
17,954

 
(71,327
)
 
$
(69,844
)
 
$
(561
)
 
$
(69,283
)
General and Administrative Expense. General and administrative expense decreased $1.6 million for the nine months ended September 30, 2017, compared to the prior year period primarily due to a decrease of $1.1 million in stock-based compensation primarily for performance-based awards and a decrease of $0.4 million in professional fees.
Other Loss. Other loss decreased $1.5 million for the nine months ended September 30, 2017 compared to the prior year period. Other loss for the nine months ended September 30, 2017 reflected a $0.4 million decrease in the fair value of shares of Invitae Corporation common stock obtained in connection with the sale of Good Start Genetics in August 2017 and an impairment of $0.2 million related to our interest in a legacy private equity fund, partially offset by a $0.4 million gain related to our Penn Mezzanine debt and equity participations. Other loss for the nine months ended September 30, 2016 reflected a $2.1 million impairment related to our Penn Mezzanine debt and equity participations partially offset by a gain of $0.4 million on the sale of Bridgevine in June 2016.
Interest Income. The increase of $1.4 million for the nine months ended September 30, 2017 compared to the prior year period was primarily attributable to higher average notes receivable from our partner companies.
Interest Expense. The increase of $2.5 million for the nine months ended September 30, 2017 compared to the prior year period was primarily attributable to $2.6 million of interest expense related to borrowings under the new credit facility we entered into in May 2017, partially offset by a $0.2 million decrease in interest expense due to the partial repurchase of $14.0 million face value of convertible senior debentures in June and July 2017.
Equity Income (Loss). Equity income (loss) decreased $71.3 million for the nine months ended September 30, 2017 compared to the prior year period. The components of equity income (loss) for the nine months ended September 30, 2017 and 2016 were as follows:

20

Nine months ended September 30, 2017:
 
Gain on sale of Good Start Genetics
$
4,250

Gain on proceeds received from escrow related to sale of Putney
704

Gain on proceeds received from escrow related to sale of Quantia
600

Gain on proceeds received from escrow related to the sale of AppFirst assets
141

Gain on sale of Nexxt (fka Beyond.com)
108

Unrealized dilution loss on the decrease of our percentage ownership in partner companies
(1,006
)
Loss on impairment of Spongecell
(3,550
)
Loss on impairment of Pneuron
(5,189
)
Share of loss of our equity method partner companies
(49,431
)
 
$
(53,373
)
Nine months ended September 30, 2016:
 
Gain on sale of Putney
$
55,638

Gain on performance milestone proceeds related to sale of Thingworx
3,264

Unrealized dilution gain on the decrease of our percentage ownership in partner companies
1,414

Gain on proceeds received from escrow related to sale of Drivefactor
1,100

Gain on proceeds received from escrow related to sale of Quantia
600

Loss on impairment of Aventura
(1,000
)
Loss on impairment of AppFirst
(1,731
)
Share of loss of our equity method partner companies
(41,331
)
 
$
17,954

The change in our share of equity loss of our equity method partner companies for the nine months ended September 30, 2017 compared to the prior year period was due to an increase in losses associated with our partner companies.
Income Tax Benefit (Expense)
Income tax benefit (expense) was $0.0 million for the three and nine months ended September 30, 2017 and 2016. We have recorded a valuation allowance to reduce our net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in the three and nine months ended September 30, 2017 was offset by changes in the valuation allowance. The tax expense that would have been recognized in the three and nine months ended September 30, 2016 was offset by changes in the valuation allowance.
Liquidity and Capital Resources
As of September 30, 2017, we had $34.3 million of cash and cash equivalents and $5.4 million of marketable securities for a total of $39.7 million. As of September 30, 2017, we had $41.0 million of principal outstanding on our 2018 Debentures, which we anticipate repaying or refinancing by the maturity date of May 15, 2018.
In May 2017, we entered into a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). As of September 30, 2017, we had $50.0 million of principal outstanding on the Credit Facility due in May 2020. The Credit Facility requires us to maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash, of at least 1.75x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of tour ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold, of at least $350 million; and (iv) certain diversification requirements and concentration limits with respect to our capital deployments to its partner companies. As of the date these consolidated financial statements were issued, we were in compliance with all of these covenants.
We fund our operations with cash and marketable securities on hand as well as proceeds from the sales of our interest in our partner companies. Due to the nature of the mergers and acquisitions market, and the developmental cycle of companies like our partner companies, our ability to generate specific amounts of liquidity from sales of our partner company interests in any given period of time cannot be assured. Accordingly, the forecasts which we utilize for projecting future compliance with covenants related to our Credit Facility include significantly discounted probability-weighted proceeds from the sales of our interests in our partner companies. Based on these forecasts, we believe we will continue to remain in compliance with all of

21

our debt covenants. Our plans to remain in compliance with these covenants include selling certain of our partner company interests in the ordinary course of our business and limiting capital deployments to new and existing partner companies.
Non-compliance with any of the covenants would constitute an event of default under the Credit Facility, and the Lender could choose to accelerate the maturity of the indebtedness. If the Lender were to accelerate the maturity of the indebtedness, we may not have sufficient immediate liquidity to repay the entire balance of our outstanding borrowings and other obligations under the Credit Facility. Should we not be in compliance with any of our debt covenants and be unable to obtain waivers for such events of default, we would pursue one of a number of potential alternatives to satisfy the obligations, including completing an equity offering or obtaining a new debt facility to refinance its existing debt.
In November 2012, we issued $55.0 million in face amount of our 5.25% convertible senior debentures due on May 15, 2018 (the "2018 Debentures"). Interest on the 2018 Debentures is payable semi-annually. At the debentures holders’ option, the 2018 Debentures are convertible into our common stock prior to November 15, 2017 subject to certain conditions, and at any time after November 15, 2017. The conversion rate of the 2018 Debentures is 55.17 shares of common stock per $1,000 principal amount of debentures, equivalent to a conversion price of approximately $18.13 per share of common stock. The closing price per share of our common stock at September 30, 2017 was $13.35. The 2018 Debentures holders have the right to require us to repurchase the 2018 Debentures if we undergo a fundamental change as defined in the debenture agreement, including the sale of all or substantially all of our common stock or assets, liquidation, or dissolution; a change in control; the delisting of our common stock from the New York Stock Exchange or the NASDAQ Global Market (or any of their respective successors); or a substantial change in the composition of our board of directors as defined in the agreement. On or after November 15, 2016, we may redeem for cash some or all of the debentures, subject to certain conditions. Upon any such redemption of the 2018 Debentures, we will pay a redemption price of 100% of their principal amount, plus accrued and unpaid interest. Upon the conversion of the 2018 Debentures we have the right to settle the conversion in stock, cash or a combination thereof.
In July and June 2017, we repurchased on the open market, and retired, an aggregate of $14.0 million face value of 2018 Debentures at a cost of $14.5 million, including transaction fees. In connection with the repurchase of these 2018 Debentures, we recognized a $0.8 million reduction in equity which is included in Accumulated Paid-In Capital in the Consolidated Balance Sheet as of September 30, 2017 and a $29 thousand loss on extinguishment of the liability which is included in Other income (loss), net in the Consolidated Statements of Operations for the nine months ended September 30, 2017. We had $41.0 million face value of 2018 Debentures outstanding at September 30, 2017 due on May 15, 2018.
We have provided a $6.3 million letter of credit that is scheduled to expire on March 31, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters which was required in connection with the sale of CompuCom Systems in 2004. The letter of credit is secured by cash which is classified as Long-term restricted cash equivalents on the Consolidated Balance Sheet. The restriction on the cash will lapse when the related letter of credit is terminated or expires on March 31, 2019.
In July 2015, the Company's Board of Directors authorized us, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the year ended December 31, 2016, we repurchased 0.4 million shares at an aggregate cost of $5.4 million with $14.6 million remaining for repurchase under the existing authorization.
We are required to return a portion or all the distributions we received as a general partner of a private equity fund for further distribution to such fund's limited partners (“clawback”). Our ownership in the fund is 19%. The clawback liability is joint and several, such that we may be required to fund the clawback for other general partners should they default. We believe our potential liability due to the possibility of default by other general partners is remote. We were notified by the fund's manager that the fund is being dissolved and $1.0 million of our clawback liability was paid in the first quarter of 2017. The maximum additional clawback liability is $0.3 million which was reflected in Other long-term liabilities on the Consolidated Balance Sheet at September 30, 2017.
Our acquisition of new partner company interests is always contingent upon our availability of cash to fund such deployments, and our timing of monetization events directly affects our availability of cash. Our ability to generate liquidity from sales of partner companies, sales of marketable securities and from equity and debt issuances has been adversely affected from time to time by adverse circumstances in the U.S. capital markets and other factors. The transactions we enter into in pursuit of our strategy could increase or decrease our liquidity at any point in time. As we seek to acquire interests in new partner companies, provide additional funding to existing partner companies, or commit capital to other initiatives, we may be required to expend our cash or incur debt, which will decrease our liquidity. Conversely, as we dispose of our interests in partner companies from time to time, we may receive proceeds from such sales, which could increase our liquidity. From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.

22

Analysis of Consolidated Cash Flows
Cash flow activity was as follows:
   
Nine months ended September 30,
   
2017
 
2016
 
Variance
   
(In thousands)
Net cash used in operating activities
$
(15,515
)
 
$
(14,114
)
 
$
(1,401
)
Net cash provided by (used in) investing activities
(1,912
)
 
39,593

 
(41,505
)
Net cash provided by (used in) financing activities
29,686

 
(5,821
)
 
35,507

   
$
12,259

 
$
19,658

 
$
(7,399
)
Net Cash Used In Operating Activities
Net cash used in operating activities increased by $1.4 million for the nine months ended September 30, 2017 compared to the prior year period. The increase was primarily due to $1.2 million of cash interest payments related to our credit facility we entered into in May 2017.
Net Cash Provided by (Used In) Investing Activities
Net cash provided by (used in) investing activities decreased by $41.5 million for the nine months ended September 30, 2017 compared to the prior year period. The decrease primarily related to a $57.3 million decrease in proceeds from the sales of and distributions from companies and a $25.1 million decrease in cash proceeds from the net change in marketable securities, partially offset by a $23.0 million decrease in acquisitions of ownership interests in companies and a $0.8 million decrease in advances and loans to companies.
Cash proceeds from the sales of and distributions from companies were $16.6 million for the nine months ended September 30, 2017 which related primarily to:
•
In March 2017, we sold our interest in partner company Nexxt, Inc., formerly Beyond.com, back to Nexxt, Inc. for $26.0 million. We received $15.5 million in cash and a three-year, $10.5 million note for the balance due, which will accrue interest at a rate of 9.5% per annum.
•
In April 2017, we received $0.7 million in connection with the expiration of the final escrow period related to the 2016 sale of Putney, Inc.
•
In March 2017, we received $0.6 million of proceeds from the sale of our participating interests in Penn Mezzanine.
•
In January 2017, we received $0.6 million in connection with the expiration of the final escrow period related to the 2015 sale of Quantia.
•
These cash proceeds were partially offset by payment of a $1.0 million clawback liability in the first quarter of 2017.
Cash proceeds from the sales of and distributions from partner companies was $73.9 million for the nine months ended September 30, 2016 which related primarily to the sale of our interests in Putney and Bridgevine, proceeds received from AppFirst from the sale of its assets, cash received from escrow associated with the sale of our interests in DriveFactor, Thingworx, and Quantia and cash received associated with the achievement of performance milestones related to the sale of our interest in Thingworx.
Net Cash Provided by (Used In) Financing Activities
Net cash provided by (used in) financing activities increased by $35.5 million for the nine months ended September 30, 2017 compared to the prior year period. The increase was primarily related to $44.3 million of net proceeds from borrowings under the Credit Facility and a decrease of $5.4 million in repurchases of our common stock, which were partially offset by $14.5 million paid to repurchase and retire $14.0 million face value of the 2018 Debentures, including transaction fees.

23

Contractual Cash Obligations and Other Commercial Commitments
There have been no material changes to the contractual cash obligations and other commercial commitments we previously disclosed under Item 7 of Part II of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017.

24

Factors That May Affect Future Results
You should carefully consider the information set forth below. The following risk factors describe situations in which our business, financial condition and/or results of operations could be materially harmed, and the value of our securities may be adversely affected. You should also refer to other information included or incorporated by reference in this report.
Our principal business depends upon our ability to make good decisions regarding the deployment of capital into new or existing partner companies and, ultimately, the performance of our partner companies, which is uncertain.
If we make poor decisions regarding the deployment of capital into new or existing partner companies, our business model will not succeed. Our success as a company ultimately depends on our ability to choose the right partner companies. If our partner companies do not succeed, the value of our assets could be significantly reduced and require substantial impairments or write-offs and our results of operations and the price of our common stock would be adversely affected. The risks relating to our partner companies include:
•
most of our partner companies have a history of operating losses and/or limited operating history;
•
the intense competition affecting the products and services our partner companies offer could adversely affect their businesses, financial condition, results of operations and prospects for growth;
•
the inability to adapt to changing marketplaces;
•
the inability to manage growth;
•
the need for additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all;
•
the inability to protect their proprietary rights and/or infringing on the proprietary rights of others;
•
that our partner companies could face legal liabilities from claims made against them based upon their operations, products or work;
•
the impact of economic downturns on their operations, results and growth prospects;
•
the inability to attract and retain qualified personnel;
•
the existence of government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies; and
•
the inability to plan for and manage catastrophic events.
These and other risks are discussed in detail under the caption “Risks Related to Our Partner Companies” below.

Our Credit Facility subjects us to interest rate risk.
In May 2017, we entered into a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). Debt service costs under the Credit Facility are subject to interest rate changes. Interest rates could rise from time to time and significantly increase our cost of borrowing. If that were to occur, replacing the Credit Facility with alternative credit arrangements having a lower cost of borrowing would likely not be possible and no assurance can be given that we would be able to refinance the Credit Facility on attractive terms or at all.

Servicing the indebtedness under the Credit Facility will require a significant amount of cash and our ability to generate cash depends on many factors beyond our control.
Our ability to make payments on the indebtedness under the Credit Facility will depend on our ability to generate cash in the future. We generate cash from proceeds we receive in connection with the sales of our interests in our partner companies. Due to the nature of the mergers and acquisitions market, and the developmental cycle of companies like our partner companies, our ability to generate specific amounts of liquidity from sales of our partner company interests in any given period of time cannot be assured. Our ability to generate cash is also, to a certain extent, subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. The risk exists that our business will be unable to generate sufficient cash flow to service our indebtedness under the Credit Facility.

Covenants in the agreements governing the Credit Facility could adversely affect our business and/or result in the operation of our business in a way other than as desired by management; our ability to comply with such covenants may be affected by events beyond our control; and a breach of any of these covenants could result in a default under the agreements governing the Credit Facility, which, if not cured or waived, could result in the acceleration of the indebtedness under the Credit Facility.
The Credit Facility contains various covenants that prohibit or limit, subject to certain exceptions, our ability to, among other things:
•
Sell, transfer, lease, convey or otherwise dispose of all or any part of our business or property;
•
Exceed concentration limits with respect to the amount of capital deployed to any single partner company;

25

•
Exceed concentration limits with respect to the amount of capital deployed to one or more partner companies operating in the same or similar industries;
•
Deploy capital to partner companies operating outside of certain specified industries;
•
Incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons;
•
Pay any dividends or make any distribution (in cash or in kind) or payment in respect of, or redeem, retire or purchase any capital stock;
•
Enter into, or permit any of our subsidiaries to enter into, any sale and leaseback transaction;
•
Wind-up, liquidate or dissolve, or merge, consolidate or amalgamate with any person, or permit any of our subsidiaries to do (or agree to do) so;
•
Enter into certain transactions with affiliates; and
•
Amend, modify or otherwise change any of our governing documents.
In addition, the Credit Facility requires us to among other things, maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash, of at least 1.75x the amount then outstanding under the Credit Facility; and (iii) a minimum aggregate appraised value of the Company’s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold, of at least $350 million.
The foregoing covenants could adversely affect our ability to finance our operations, make strategic acquisitions, engage in business activities that may be in our interest and plan for or react to market conditions or otherwise execute our business strategies.
Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.
Our failure to comply with any of these covenants could result in a default under the Credit Facility. If that were to occur, the Lender could choose to accelerate the maturity of the indebtedness. If the Lender were to accelerate the maturity of the indebtedness, we may not have sufficient immediate liquidity to repay the entire balance of the outstanding borrowings and other obligations under the Credit Facility.
Our partner companies (and the nature of our interests in them) could vary widely from period to period.
As part of our strategy, we continually assess the value to our shareholders of our interests in our partner companies. We also regularly evaluate alternative uses for our capital resources. As a result, depending on market conditions, growth prospects and other key factors, we may at any time:
•
change the individual and/or types of partner companies on which we focus;
•
sell some or all of our interests in any of our partner companies; or
•
otherwise change the nature of our interests in our partner companies.
Therefore, the nature of our holdings could vary significantly from period to period.
Our consolidated financial results also may vary significantly based upon which, if any, of our partner companies are included in our Consolidated Financial Statements.
A significant amount of our deployed capital may be concentrated in partner companies operating in the same or similar industries, limiting the diversification of our capital deployments.
Except as may be agreed to with our debt providers, we do not have fixed guidelines for diversification of capital deployments, and our capital deployments could be concentrated in several partner companies that operate in the same or similar industries. This may cause us to be more susceptible to any single economic, regulatory or other occurrence affecting those particular industries than we would otherwise be if our partner companies operated in more diversified industries.
Our business model does not rely upon, or plan for, the receipt of operating cash flows from our partner companies. Our partner companies generally provide us with no cash flow from their operations. We rely on cash on hand, liquidity events and our ability to generate cash from capital raising activities to finance our operations.
We need capital to develop new partner company relationships and to fund the capital needs of our existing partner companies. We also need cash to service and repay our outstanding debt, finance our corporate overhead and meet our existing funding commitments. As a result, we have substantial cash requirements. Our partner companies generally provide us with no cash flow from their operations. To the extent our partner companies generate any cash from operations, they generally retain the funds to develop their own businesses. As a result, we must rely on cash on hand, partner company liquidity events and new capital raising activities to meet our cash needs. If we are unable to find ways of monetizing our holdings or raising additional

26

capital on attractive terms, we may face liquidity issues that will require us to curtail our new business efforts, constrain our ability to execute our business strategy and limit our ability to provide financial support to our existing partner companies.
Fluctuations in the price of the common stock of our publicly traded holdings may affect the price of our common stock.
From time to time, we may hold equity interests in companies that are publicly traded. Fluctuations in the market prices of the common stock of publicly traded holdings may affect the price of our common stock. Historically, the market prices of our publicly traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance.
Intense competition from other capital providers for interests in companies could adversely affect our ability to deploy capital and result in higher valuations of partner company interests which could result in lower gains or possibly losses on our partner companies.
We face intense competition from other capital providers as we acquire and develop interests in our partner companies. Some of our competitors have more experience identifying, acquiring and selling companies and have greater financial and management resources, brand name recognition or industry contacts than we have. Competition from other capital providers could adversely affect our ability to deploy capital. In addition, despite making most of our acquisitions at a stage when our partner companies are not publicly traded, we may still pay higher prices for those equity interests because of higher valuations of similar public companies and competition from other acquirers and capital providers, which could result in lower gains or possibly losses.

We may be unable to obtain maximum value for our holdings or to sell our holdings on a timely basis.
We hold significant positions in our partner companies. Consequently, if we were to divest all or part of our holdings in a partner company, we may have to sell our interests at a relative discount to a price which may be received by a seller of a smaller portion. For partner companies with publicly traded stock, we may be unable to sell our holdings at then-quoted market prices. The trading volume and public float in the common stock of a publicly traded partner company may be small relative to our holdings. As a result, any significant open-market divestiture by us of our holdings in such a partner company, if possible at all, would likely have a material adverse effect on the market price of its common stock and on our proceeds from such a divestiture. Additionally, we may not be able to take our partner companies public as a means of monetizing our position or creating shareholder value.
Registration and other requirements under applicable securities laws and contractual restrictions also may adversely affect our ability to dispose of our partner company holdings on a timely basis.
Our success is dependent on our senior management.
Our success is dependent on our senior management team’s ability to execute our strategy. A loss of one or more of the members of our senior management team without adequate replacement could have a material adverse effect on us.
Our business strategy may not be successful if valuations in the market sectors in which our partner companies participate decline.
Our strategy involves creating value for our shareholders by helping our partner companies build value and, if appropriate, accessing the public and private capital markets. Therefore, our success is dependent on the value of our partner companies as determined by the public and private capital markets. Many factors, including reduced market interest, may cause the market value of our partner companies to decline. If valuations in the market sectors in which our partner companies participate decline, their access to the public and private capital markets on terms acceptable to them may be limited.
Our partner companies could make business decisions that are not in our best interests or with which we do not agree, which could impair the value of our holdings.
Although we may seek a controlling or influential equity interest and participation in the management of our partner companies, we may not be able to control the significant business decisions of our partner companies. We may have shared control or no control over some of our partner companies. In addition, although we currently own a significant, influential interest in some of our partner companies, we do not maintain a controlling interest in any of our partner companies. Acquisitions of interests in partner companies in which we share or have no control, and the dilution of our interests in or loss of control of partner companies, will involve additional risks that could cause the performance of our interests and our operating results to suffer, including:
•
the management of a partner company having economic or business interests or objectives that are different from ours; and

27

•
the partner companies not taking our advice with respect to the financial or operating issues they may encounter.
Our inability to control our partner companies also could prevent us from assisting them, financially or otherwise, or could prevent us from liquidating our interests in them at a time or at a price that is favorable to us. Additionally, our partner companies may not act in ways that are consistent with our business strategy. These factors could hamper our ability to maximize returns on our interests and cause us to incur losses on our interests in these partner companies.
We may have to buy, sell or retain assets when we would otherwise not wish to do so in order to avoid registration under the Investment Company Act.
The Investment Company Act of 1940 regulates companies which are engaged primarily in the business of investing, reinvesting, owning, holding or trading in securities. Under the Investment Company Act, a company may be deemed to be an investment company if it owns investment securities with a value exceeding 40% of the value of its total assets (excluding government securities and cash items) on an unconsolidated basis, unless an exemption or safe harbor applies. We refer to this test as the “40% Test.” Securities issued by companies other than consolidated partner companies are generally considered “investment securities” for purposes of the Investment Company Act, unless other circumstances exist which actively involve the company holding such interests in the management of the underlying company. We are a company that partners with growth-stage companies to build value; we are not engaged primarily in the business of investing, reinvesting or trading in securities. We are in compliance with the 40% Test. Consequently, we do not believe that we are an investment company under the Investment Company Act.
We monitor our compliance with the 40% Test and seek to conduct our business activities to comply with this test. It is not feasible for us to be regulated as an investment company because the Investment Company Act rules are inconsistent with our strategy of actively helping our partner companies in their efforts to build value. In order to continue to comply with the 40% Test, we may need to take various actions which we would otherwise not pursue. For example, we may need to retain a controlling interest in a partner company that we no longer consider strategic, we may not be able to acquire an interest in a company unless we are able to obtain a controlling ownership interest in the company, or we may be limited in the manner or timing in which we sell our interests in a partner company. Our ownership levels also may be affected if our partner companies are acquired by third parties or if our partner companies issue stock which dilutes our ownership interest. The actions we may need to take to address these issues while maintaining compliance with the 40% Test could adversely affect our ability to create and realize value at our partner companies.

Economic disruptions and downturns may have negative repercussions for us.
Events in the United States and international capital markets, debt markets and economies may negatively impact our stock price and our ability to pursue certain tactical and strategic initiatives, such as accessing additional public or private equity or debt financing for us or for our partner companies and selling our interests in partner companies on terms acceptable to us and in time frames consistent with our expectations.
We cannot provide assurance that material weaknesses in our internal control over financial reporting will not be identified in the future.
We cannot assure you that material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in a material weakness, or could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.
Risks Related to Our Partner Companies
Most of our partner companies have a history of operating losses and/or limited operating history and may never be profitable.
Most of our partner companies have a history of operating losses and/or limited operating history, have significant historical losses and may never be profitable. Many have incurred substantial costs to develop and market their products, have incurred net losses and cannot fund their cash needs from operations. We expect that the operating expenses of certain of our partner companies will increase substantially in the foreseeable future as they continue to develop products and services, increase sales and marketing efforts, and expand operations.

28

Our partner companies face intense competition, which could adversely affect their business, financial condition, results of operations and prospects for growth.
There is intense competition in the technology marketplaces, and we expect competition to intensify in the future. Our business, financial condition, results of operations and prospects for growth will be materially adversely affected if our partner companies are not able to compete successfully. Many of the present and potential competitors may have greater financial, technical, marketing and other resources than those of our partner companies. This may place our partner companies at a disadvantage in responding to the offerings of their competitors, technological changes or changes in client requirements. Also, our partner companies may be at a competitive disadvantage because many of their competitors have greater name recognition, more extensive client bases and a broader range of product offerings. In addition, our partner companies may compete against one another.
The success or failure of many of our partner companies is dependent upon the ultimate effectiveness of newly-created technologies, medical devices, financial services, healthcare diagnostics, etc.
Our partner companies’ business strategies are often highly dependent upon the successful launch and commercialization of an innovative technology or device, including, without limitation, technologies or devices used in healthcare, financial services or digital media.  Despite all of our efforts to understand the research and development underlying the innovation or creation of such technologies and devices before we deploy capital into a partner company, sometimes the performance of the technology or device does not match our expectations or those of our partner company. In those situations, it is likely that we will incur a partial or total loss of the capital which we deployed in such partner company.
Our partner companies may fail if they do not adapt to changing marketplaces.
If our partner companies fail to adapt to changes in technology and customer and supplier demands, they may not become or remain profitable. There is no assurance that the products and services of our partner companies will achieve or maintain market penetration or commercial success, or that the businesses of our partner companies will be successful.

The technology marketplaces are characterized by:
•
rapidly changing technology;
•
evolving industry standards;
•
frequent introduction of new products and services;
•
shifting distribution channels;
•
evolving government regulation;
•
frequently changing intellectual property landscapes; and
•
changing customer demands.
Our future success will depend on our partner companies’ ability to adapt to these evolving marketplaces. They may not be able to adequately or economically adapt their products and services, develop new products and services or establish and maintain effective distribution channels for their products and services. If our partner companies are unable to offer competitive products and services or maintain effective distribution channels, they will sell fewer products and services and forego potential revenue, possibly causing them to lose money. In addition, we and our partner companies may not be able to respond to the marketplace changes in an economically efficient manner, and our partner companies may become or remain unprofitable.
Our partner companies may grow rapidly and may be unable to manage their growth.
We expect some of our partner companies to grow rapidly. Rapid growth often places considerable operational, managerial and financial strain on a business. To successfully manage rapid growth, our partner companies must, among other things:
•
improve, upgrade and expand their business infrastructures;
•
scale up production operations;
•
develop appropriate financial reporting controls;
•
attract and retain qualified personnel; and
•
maintain appropriate levels of liquidity.
If our partner companies are unable to manage their growth successfully, their ability to respond effectively to competition and to achieve or maintain profitability will be adversely affected.


29

Based on our business model, some or all of our partner companies will need to raise additional capital to fund their operations at any given time. We may not be able to fund some or all of such amounts and such amounts may not be available from third parties on acceptable terms, if at all. Further, if our partner companies do raise additional capital, either debt or equity, such capital may rank senior to our interests in such companies.
We cannot be certain that our partner companies will be able to obtain additional financing on favorable terms when needed, if at all. Because our resources and our ability to raise capital are not unlimited, we may not be able to provide partner companies with sufficient capital resources to enable them to reach a cash-flow positive position or a sale of the company, even if we wish to do so. General economic disruptions and downturns may also negatively affect the ability of some of our partner companies to fund their operations from other stockholders and capital sources. We also may fail to accurately project the capital needs of partner companies. If partner companies need capital but are not able to raise capital from us or other outside sources, then they may need to cease or scale back operations. In such event, our interest in any such partner company will become less valuable. If our partner companies raise additional capital, either debt or equity, that ranks senior to the capital we have deployed, such capital may entitle its holders to receive returns of capital before the dates on which we are entitled to receive any return of our deployed capital. Also, in the event of any insolvency, liquidation, dissolution, reorganization or bankruptcy of a partner company, holders of such partner company’s instruments that rank senior to our deployed capital will typically be entitled to receive payment in full before we receive any return of our deployed capital. After returning such senior capital, such partner company may not have any remaining assets to use for returning capital to us, causing us to lose some or all of our deployed capital in such partner company.
Economic disruptions and downturns may negatively affect our partner companies’ plans and their results of operations.
Many of our partner companies are largely dependent upon outside sources of capital to fund their operations. Disruptions in the availability of capital from such sources will negatively affect the ability of such partner companies to pursue their business models and will force such companies to revise their growth and development plans accordingly. Any such changes will, in turn, negatively affect our ability to realize the value of our capital deployments in such partner companies.

In addition, downturns in the economy as well as possible governmental responses to such downturns and/or to specific situations in the economy could affect the business prospects of certain of our partner companies, including, but not limited to, in the following ways: weaknesses in the financial services industries; reduced business and/or consumer spending; and/or systemic changes in the ways the healthcare system operates in the United States.
Some of our partner companies may be unable to protect their proprietary rights and may infringe on the proprietary rights of others.
Our partner companies assert various forms of intellectual property protection. Intellectual property may constitute an important part of partner company assets and competitive strengths. Federal law, most typically copyright, patent, trademark and trade secret laws, generally protects intellectual property rights. Although we expect that our partner companies will take reasonable efforts to protect the rights to their intellectual property, third parties may develop similar intellectual property independently. Moreover, the complexity of international trade secret, copyright, trademark and patent law, coupled with the limited resources of our partner companies and the demands of quick delivery of products and services to market, create a risk that partner company efforts to prevent misappropriation of their technology will prove inadequate.
Some of our partner companies also license intellectual property from third parties and it is possible that they could become subject to infringement actions based upon their use of the intellectual property licensed from those third parties. Our partner companies generally obtain representations as to the origin and ownership of such licensed intellectual property. However, this may not adequately protect them. Any claims against our partner companies’ proprietary rights, with or without merit, could subject the companies to costly litigation and divert their technical and management personnel from other business concerns. If our partner companies incur costly litigation and their personnel are not effectively deployed, the expenses and losses incurred by our partner companies will increase and their profits, if any, will decrease.
Third parties have and may assert infringement or other intellectual property claims against our partner companies based on their patents or other intellectual property claims. Even though we believe our partner companies’ products do not infringe any third party’s patents, they may have to pay substantial damages, possibly including treble damages, if it is ultimately determined that they do. They may have to obtain a license to sell their products if it is determined that their products infringe on another person’s intellectual property. Our partner companies might be prohibited from selling their products before they obtain a license, which, if available at all, may require them to pay substantial royalties. Even if infringement claims against our partner companies are without merit, defending these types of lawsuits takes significant time, is expensive and may divert management attention from other business concerns.

30

Certain of our partner companies could face legal liabilities from claims made against their operations, products or work.
Because manufacture and sale of certain partner company products entail an inherent risk of product liability, certain partner companies maintain product liability insurance. Although none of our current partner companies have experienced any material losses in this regard, there can be no assurance that they will be able to maintain or acquire adequate product liability insurance in the future and any product liability claim could have a material adverse effect on a partner company’s financial stability, revenues and results of operations. In addition, many of the engagements of our partner companies involve projects that are critical to the operation of their clients’ businesses. If our partner companies fail to meet their contractual obligations, they could be subject to legal liability, which could adversely affect their business, operating results and financial condition. Partner company contracts typically include provisions designed to limit their exposure to legal claims relating to their services and products. However, these provisions may not protect our partner companies or may not be enforceable. Also, some of our partner companies depend on their relationships with their clients and their reputation for high-quality services and integrity to retain and attract clients. As a result, claims made against our partner companies’ work may damage their reputation, which in turn could impact their ability to compete for new work and negatively impact their revenue and profitability.
Our partner companies’ success depends on their ability to attract and retain qualified personnel.
Our partner companies depend upon their ability to attract and retain senior management and key personnel, including trained technical and marketing personnel. Our partner companies also will need to continue to hire additional personnel as they expand. Although our current partner companies have not been the subject of a work stoppage, any future work stoppage could have a material adverse effect on their respective operations. A shortage in the availability of the requisite qualified personnel or work stoppage would limit the ability of our partner companies to grow, to increase sales of their existing products and services, and to launch new products and services.

Government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies.
Failure to comply with applicable requirements of the FDA or comparable regulation in foreign countries can result in fines, recall or seizure of products, total or partial suspension of production, withdrawal of existing product approvals or clearances, refusal to approve or clear new applications or notices and criminal prosecution. Manufacturers of pharmaceuticals and medical diagnostic devices and operators of laboratory facilities are subject to strict federal and state regulation regarding validation and the quality of manufacturing and laboratory facilities. Failure to comply with these quality regulation systems requirements could result in civil or criminal penalties or enforcement proceedings, including the recall of a product or a “cease distribution” order. The enactment of any additional laws or regulations that affect healthcare insurance policy and reimbursement (including Medicare reimbursement) could negatively affect some of our partner companies. If Medicare or private payers change the rates at which our partner companies or their customers are reimbursed by insurance providers for their products, such changes could adversely impact our partner companies.
Some of our partner companies may be subject to significant environmental, health and safety regulation.
Some of our partner companies may be subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as to the safety and health of manufacturing and laboratory employees. In addition, the federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety. Compliance with such regulations could increase operating costs at certain of our partner companies, and the failure to comply could negatively affect the operations and results of some of our partner companies.
Catastrophic events may disrupt our partner companies’ businesses.
Some of our partner companies are highly automated businesses and rely on their network infrastructure, various software applications and many internal technology systems and data networks for their customer support, development, sales and marketing and accounting and finance functions. Further, some of our partner companies provide services to their customers from data center facilities in multiple locations. Some of these data centers are operated by third parties, and the partner companies have limited control over those facilities. A disruption or failure of these systems or data centers in the event of a natural disaster, telecommunications failure, power outage, cyber-attack, war, terrorist attack or other catastrophic event could cause system interruptions, reputational harm, delays in product development, breaches of data security and loss of critical data. Such an event could also prevent the partner companies from fulfilling customer orders or maintaining certain service level requirements, particularly in respect of their SaaS offerings. While certain of our partner companies have developed certain disaster recovery plans and maintain backup systems to reduce the potentially adverse effect of such events, a catastrophic event that resulted in the destruction or disruption of any of their data centers or their critical business or

31

information technology systems could severely affect their ability to conduct normal business operations and, as a result, their business, operating results and financial condition could be adversely affected.
We cannot provide assurance that our partner companies’ disaster recovery plans will address all of the issues they may encounter in the event of a disaster or other unanticipated issue, and their business interruption insurance may not adequately compensate them for losses that may occur from any of the foregoing. In the event that a natural disaster, terrorist attack or other catastrophic event were to destroy any part of their facilities or interrupt their operations for any extended period of time, or if harsh weather or health conditions prevent them from delivering products in a timely manner, their business, financial condition and operating results could be adversely affected.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to the information we previously disclosed under Item 7A of Part II of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017.
Item 4.  Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of September 30, 2017 are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
None.  

Item 1A. Risk Factors
Except as included under the heading “Factors That May Affect Future Results” above, there have been no material changes in our risk factors from the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2016.


32


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about purchases of equity securities by the Company and affiliated purchasers of the Company, during the quarter ended September 30, 2017, which equity securities are registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"):
Period
Total Number
of Shares
Purchased (a)
 
Average
Price Paid
Per Share
 
Total Number of Shares
Purchased as Part of
Publicly Announced
Plan (b)
 
Maximum Number (or Approximate Dollar Value) of
Shares that May Yet Be
Purchased Under the
Plan (b)
July 1, 2017 - July 31, 2017
1,062

 
$
12.6300

 
—

 
$
14,636,135

August 1, 2017 - August 31, 2017
163

 
$
11.8000

 
—

 
$
14,636,135

September 1, 2017 - September 30, 2017
2,258

 
$
12.9500

 
—

 
$
14,636,135

Total
3,483

 
$
12.7500

 
—

 
 
(a) During the third quarter of 2017, the Company repurchased an aggregate of 3 thousand shares of its common stock initially issued as restricted stock awards to employees and subsequently withheld from employees to satisfy the statutory withholding tax liability upon the vesting of such restricted stock awards.
(b) In July 2015, our Board of Directors authorized the Company to repurchase shares of its outstanding common stock with an aggregate value of up to $25.0 million.  These repurchases may be made in open market or privately negotiated transactions, including under plans complying with Rule 10b5-1 of the Exchange Act, based on market conditions, stock price, and other factors.  The share repurchase program does not obligate the Company to acquire any specific number of shares.
Item 3. Defaults Upon Senior Securities
None.

Item 4. Mine Safety Disclosures
Not applicable.

Item 5. Other Information
None.

33


Item 6.  Exhibits
(a) Exhibits.
The following is a list of exhibits required by Item 601 of Regulation S-K to be filed as part of this Report. For exhibits that previously have been filed, the Registrant incorporates those exhibits herein by reference. Documents which are incorporated by reference to filings by parties other than the Registrant are identified in a footnote to this table.
Exhibit Number
      
Description
   
 
 
 
 
31.1 †
      
      
   
   
   
   
31.2 †
      
      
   
   
   
   
32.1 ‡
      
      
   
   
   
   
32.2 ‡
      
      
   
   
   
   
101  
      
The following materials from Safeguard Scientifics, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in XBRL (eXtensible Business Reporting Language); (i) Consolidated Balance Sheets (unaudited); (ii) Consolidated Statements of Operations (unaudited); (iii) Consolidated Statements of Comprehensive Income (Loss) (unaudited); (iv) Condensed Consolidated Statements of Cash Flows (unaudited); (v) Consolidated Statement of Changes in Equity (unaudited); and (vi) Notes to Consolidated Financial Statements (unaudited).
      
   
   
   
   
†
Filed herewith
‡
Furnished herewith



34


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
   
   
   
 
SAFEGUARD SCIENTIFICS, INC.
Date:
October 26, 2017
/s/    Stephen T. Zarrilli        
   
 
Stephen T. Zarrilli
   
 
President and Chief Executive Officer
Date:
October 26, 2017
/s/    Jeffrey B. McGroarty        
   
 
Jeffrey B. McGroarty
   
 
Senior Vice President and Chief Financial Officer

35
 EX-31.1 2 sfe-2017xq3xex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
   
CERTIFICATION
   
I, Stephen T. Zarrilli, certify that:
   
1.
I have reviewed this Quarterly Report on Form 10-Q of Safeguard Scientifics, Inc.;
   
   
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
   
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
   
   
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
   
   
   
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
   
   
   
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
   
   
   
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
   
   
   
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
   
   
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
   
   
   
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
   
   
   
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
   
   
   
 
SAFEGUARD SCIENTIFICS, INC.
   
 
   
Date:
October 26, 2017
/s/ Stephen T. Zarrilli
   
 
Stephen T. Zarrilli
   
 
President and Chief Executive Officer


 EX-31.2 3 sfe-2017xq3xex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
   
CERTIFICATION
   
I, Jeffrey B. McGroarty, certify that:
   
1.
I have reviewed this Quarterly Report on Form 10-Q of Safeguard Scientifics, Inc.;
   
   
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
   
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
   
   
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
   
   
   
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
   
   
   
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
   
   
   
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
   
   
   
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
   
   
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
   
   
   
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
   
   
   
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
   
   
   
 
SAFEGUARD SCIENTIFICS, INC.
   
 
   
Date:
October 26, 2017
/s/ Jeffrey B. McGroarty
   
 
Jeffrey B. McGroarty
   
 
Senior Vice President and Chief Financial Officer







 EX-32.1 4 sfe-2017xq3xex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
   
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
   
In connection with the Quarterly Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-Q for the nine months ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen T. Zarrilli, President and Chief Executive Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
   
1.
The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and
   
   
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.
   
   
   
 
SAFEGUARD SCIENTIFICS, INC.
   
 
   
Date:
October 26, 2017
/s/ Stephen T. Zarrilli
   
 
Stephen T. Zarrilli
   
 
President and Chief Executive Officer


 EX-32.2 5 sfe-2017xq3xex322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
   
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
   
In connection with the Quarterly Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-Q for the nine months ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey B. McGroarty, Senior Vice President and Chief Financial Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
   
1.
The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and
   
   
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.
   
   
   
 
SAFEGUARD SCIENTIFICS, INC.
   
 
   
Date:
October 26, 2017
/s/ Jeffrey B. McGroarty
   
 
Jeffrey B. McGroarty
   
 
Senior Vice President and Chief Financial Officer


 EX-101.INS 6 sfe-20170930.xml XBRL INSTANCE DOCUMENT 0000086115 2017-01-01 2017-09-30 0000086115 2017-10-24 0000086115 2017-09-30 0000086115 2016-12-31 0000086115 2017-07-01 2017-09-30 0000086115 2016-07-01 2016-09-30 0000086115 2016-01-01 2016-09-30 0000086115 2015-12-31 0000086115 2016-09-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000086115 us-gaap:TreasuryStockMember 2017-01-01 2017-09-30 0000086115 us-gaap:RetainedEarningsMember 2017-09-30 0000086115 us-gaap:RetainedEarningsMember 2016-12-31 0000086115 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000086115 us-gaap:CommonStockMember 2017-09-30 0000086115 us-gaap:TreasuryStockMember 2017-09-30 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000086115 us-gaap:TreasuryStockMember 2016-12-31 0000086115 us-gaap:CommonStockMember 2016-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000086115 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-05-31 0000086115 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-09-30 0000086115 us-gaap:ConvertibleDebtMember 2017-09-30 0000086115 sfe:QuantiaInc.Member 2017-01-01 2017-01-31 0000086115 sfe:BeyondComIncMember 2017-03-01 2017-03-31 0000086115 sfe:GoodStartGeneticsIncMember 2017-08-01 2017-08-31 0000086115 sfe:PutneyIncMember 2016-04-01 2016-04-30 0000086115 sfe:PneuronMember 2017-01-01 2017-03-31 0000086115 sfe:PneuronMember 2017-09-30 0000086115 sfe:BeyondComIncMember 2017-03-03 0000086115 sfe:PneuronMember 2017-04-01 2017-06-30 0000086115 sfe:PutneyIncMember 2017-01-01 2017-06-30 0000086115 sfe:QuantiaInc.Member 2017-01-01 2017-09-30 0000086115 sfe:QuantiaInc.Member 2015-07-01 2015-07-31 0000086115 sfe:SpongecellIncMember 2017-04-01 2017-06-30 0000086115 sfe:BeyondComIncMember 2017-01-01 2017-09-30 0000086115 sfe:GoodStartGeneticsIncMember 2017-01-01 2017-09-30 0000086115 sfe:QuantiaInc.Member 2016-07-01 2016-07-31 0000086115 sfe:PutneyIncMember 2017-04-01 2017-04-30 0000086115 us-gaap:OtherOwnershipInterestMember 2016-12-31 0000086115 us-gaap:OtherOwnershipInterestMember 2017-09-30 0000086115 us-gaap:PrivateEquityFundsMember 2016-12-31 0000086115 us-gaap:PrivateEquityFundsMember 2017-09-30 0000086115 sfe:LumesisIncMember 2017-01-01 2017-03-31 0000086115 sfe:MeQuilibriumMember 2017-07-01 2017-09-30 0000086115 sfe:InfoBionicMember 2017-01-01 2017-09-30 0000086115 sfe:WebLincMember 2017-01-01 2017-06-30 0000086115 sfe:FullMeasureMember 2016-01-01 2016-12-31 0000086115 sfe:MeQuilibriumMember 2016-01-01 2016-12-31 0000086115 sfe:HooplaSoftwareIncMember 2017-07-01 2017-09-30 0000086115 sfe:TriceMember 2016-01-01 2016-12-31 0000086115 sfe:AktanaInc.Member 2017-04-01 2017-06-30 0000086115 sfe:HooplaSoftwareIncMember 2016-01-01 2016-12-31 0000086115 sfe:QuanticMindMember 2016-01-01 2016-12-31 0000086115 sfe:SonobiMember 2017-04-01 2017-06-30 0000086115 sfe:AventuraMember 2016-01-01 2016-12-31 0000086115 sfe:NovaSomIncMember 2017-01-01 2017-09-30 0000086115 sfe:InfoBionicMember 2016-01-01 2016-12-31 0000086115 sfe:QuanticMindMember 2017-07-01 2017-09-30 0000086115 sfe:CaskDataMember 2016-01-01 2016-12-31 0000086115 sfe:WebLincMember 2016-01-01 2016-12-31 0000086115 sfe:CloudMineMember 2016-01-01 2016-12-31 0000086115 sfe:AktanaInc.Member 2016-01-01 2016-12-31 0000086115 sfe:NovaSomIncMember 2016-01-01 2016-12-31 0000086115 sfe:AventuraMember 2017-09-30 0000086115 sfe:SonobiMember 2016-01-01 2016-12-31 0000086115 sfe:GoodStartGeneticsIncMember 2016-01-01 2016-12-31 0000086115 sfe:TriceMember 2017-04-01 2017-06-30 0000086115 sfe:CloudMineMember 2017-01-01 2017-03-31 0000086115 sfe:AventuraMember 2017-01-01 2017-03-31 0000086115 sfe:LumesisIncMember 2016-01-01 2016-12-31 0000086115 sfe:FullMeasureMember 2017-01-01 2017-03-31 0000086115 sfe:CaskDataMember 2017-01-01 2017-09-30 0000086115 sfe:GoodStartGeneticsIncMember 2017-04-01 2017-06-30 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-09-30 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-09-30 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-09-30 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2017-09-30 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2016-12-31 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2016-12-31 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2016-12-31 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2016-12-31 0000086115 sfe:InterestRateApplicationBMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-05-01 2017-05-31 0000086115 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-05-01 2017-05-31 0000086115 us-gaap:ConvertibleDebtMember 2017-01-01 2017-09-30 0000086115 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-01-01 2017-09-30 0000086115 sfe:InterestRateApplicationAMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-31 0000086115 us-gaap:ConvertibleDebtMember 2012-11-30 0000086115 sfe:InterestRateApplicationBMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-31 0000086115 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-06-30 0000086115 us-gaap:ConvertibleDebtMember 2016-01-01 2016-09-30 0000086115 sfe:InterestRateApplicationAMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-31 0000086115 us-gaap:ConvertibleDebtMember 2017-07-01 2017-09-30 0000086115 sfe:InterestRateApplicationBMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:MinimumMember 2017-05-01 2017-05-31 0000086115 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-07-01 2017-09-30 0000086115 sfe:InterestRateApplicationBMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2017-05-01 2017-05-31 0000086115 us-gaap:ConvertibleDebtMember 2016-07-01 2016-09-30 0000086115 sfe:ServiceBasedAwardMember 2017-01-01 2017-09-30 0000086115 sfe:ServiceBasedAwardMember 2016-01-01 2016-09-30 0000086115 sfe:DeferredStockUnitsMember 2017-01-01 2017-09-30 0000086115 sfe:DeferredStockUnitsMember us-gaap:DirectorMember 2016-01-01 2016-09-30 0000086115 us-gaap:PerformanceSharesMember 2017-01-01 2017-09-30 0000086115 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000086115 sfe:RestrictedStockUnitAndPerformanceStockUnitAndDeferredStockUnitMember 2016-01-01 2016-09-30 0000086115 us-gaap:PerformanceSharesMember 2016-07-01 2016-09-30 0000086115 sfe:ServiceBasedAwardMember 2017-07-01 2017-09-30 0000086115 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000086115 us-gaap:PerformanceSharesMember 2017-07-01 2017-09-30 0000086115 sfe:DeferredStockUnitsMember us-gaap:DirectorMember 2017-01-01 2017-09-30 0000086115 us-gaap:PerformanceSharesMember 2016-01-01 2016-09-30 0000086115 sfe:ServiceBasedAwardMember 2016-07-01 2016-09-30 0000086115 sfe:RestrictedStockUnitAndPerformanceStockUnitAndDeferredStockUnitMember 2016-07-01 2016-09-30 0000086115 sfe:RestrictedStockUnitAndPerformanceStockUnitAndDeferredStockUnitMember 2017-01-01 2017-09-30 0000086115 sfe:RestrictedStockUnitAndPerformanceStockUnitAndDeferredStockUnitMember 2017-07-01 2017-09-30 0000086115 sfe:GeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0000086115 sfe:GeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0000086115 sfe:GeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0000086115 sfe:GeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0000086115 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000086115 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0000086115 sfe:RestrictedStockUnitAndPerformanceStockUnitAndDeferredStockUnitMember 2016-07-01 2016-09-30 0000086115 sfe:ConvertibleSeniorDebenturesDueTwoThousandEighteenMember 2016-01-01 2016-09-30 0000086115 sfe:RestrictedStockUnitAndPerformanceStockUnitAndDeferredStockUnitMember 2017-07-01 2017-09-30 0000086115 sfe:ConvertibleSeniorDebenturesDueTwoThousandEighteenMember 2017-07-01 2017-09-30 0000086115 sfe:InfoBionicMember sfe:HealthcareMember 2017-09-30 0000086115 sfe:WebLincMember 2017-09-30 0000086115 sfe:AdvantedgeHealthcareSolutionsIncMember 2017-09-30 0000086115 sfe:MediaMathIncMember 2017-09-30 0000086115 sfe:PropellerMember sfe:HealthcareMember 2017-09-30 0000086115 sfe:TriceMember sfe:HealthcareMember 2017-09-30 0000086115 sfe:ClutchMember 2017-09-30 0000086115 sfe:BrickWorkMember 2017-09-30 0000086115 sfe:FullMeasureMember 2017-09-30 0000086115 sfe:TransactisMember 2017-09-30 0000086115 sfe:HooplaSoftwareIncMember 2017-09-30 0000086115 sfe:CloudMineMember 2017-09-30 0000086115 sfe:ApprendaMember 2017-09-30 0000086115 sfe:TREXGroupInc.Member 2017-09-30 0000086115 sfe:LumesisIncMember 2017-09-30 0000086115 sfe:QuanticMindInc.Member 2017-09-30 0000086115 sfe:MeQuilibriumMember sfe:HealthcareMember 2017-09-30 0000086115 sfe:SyapseInc.Member sfe:HealthcareMember 2017-09-30 0000086115 sfe:CaskDataMember 2017-09-30 0000086115 sfe:MoxeHealthMember 2017-09-30 0000086115 sfe:SpongecellMember 2017-09-30 0000086115 sfe:NovaSomIncMember sfe:HealthcareMember 2017-09-30 0000086115 sfe:PrognosMember 2017-09-30 0000086115 sfe:AktanaInc.Member sfe:HealthcareMember 2017-09-30 0000086115 sfe:SonobiMember 2017-09-30 0000086115 sfe:ZipnosisMember sfe:HealthcareMember 2017-09-30 0000086115 sfe:ClawbackLiabilityMember 2017-09-30 0000086115 sfe:AccruedExpensesAndOtherCurrentLiabilitiesMember 2017-09-30 0000086115 sfe:OtherLongTermLiabilitiesMember 2017-09-30 0000086115 us-gaap:EmployeeSeveranceMember 2017-09-30 0000086115 us-gaap:LetterOfCreditMember 2017-09-30 0000086115 2001-10-01 2001-10-31 0000086115 sfe:ClawbackLiabilityMember 2017-03-31 0000086115 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0000086115 us-gaap:CommonStockMember 2016-09-30 0000086115 us-gaap:CommonStockMember 2015-07-31 iso4217:USD xbrli:shares sfe:nonconsolidated_partner_company xbrli:pure sfe:vesting_type xbrli:shares utreg:Y sfe:segment iso4217:USD false --12-31 Q3 2017 2017-09-30 10-Q 0000086115 20412398 Accelerated Filer SAFEGUARD SCIENTIFICS INC SFE 39700000 32838000 52496000 28394000 40653000 19658000 12259000 0 1000000 0.19 300000 200000 1800000 3000000 2000000 300000 1600000 4900000 1500000 41000000 20000000 350000000 1.75 50000000 650000 65 1400000 0.095 414237 137125 P3Y 0 0 0 50000 3000 13000 274000 277000 26 1 0.25 284000 P1Y 2 140000 171000 2223000 2495000 -431000 -104000 816016000 815031000 806000 806000 25142000 20289000 604000 604000 1879000 1879000 560000 560000 806000 806000 500000 100000 0 1500000 100000 200000 500000 0 0 1000000 100000 200000 400000 1200000 400000 1600000 400000 600000 600000 700000 3000000 2300000 900000 600000 2700000 2200000 3600000 231828000 194285000 32551000 47060000 22058000 34300000 34317000 22058000 0 0 22058000 34317000 0 0 34317000 0.10 0.10 83333000 83333000 21573000 21573000 2157000 2157000 -24082000 -548000 -18376000 -69517000 0 40148000 40100000 52560000 0 3662000 2112000 1550000 4096000 2762000 1334000 0.01 0.085 0.02 0.075 0.005 0.01 50000000 5700000 41000000 55000000.0 42200000 0.145 0.087 0.0525 14000000 P3Y 5100000 43000 50000 1800000 900000 20387000 20390000 20455000 20416000 -1.18 -0.03 -0.91 -3.42 -1.18 -0.03 -0.91 -3.42 3498000 2844000 0.401 0.245 0.294 0.203 0.313 0.474 0.427 0.423 0.255 0.395 0.438 0.370 0.204 0.324 0.317 0.352 0.240 0.247 0.216 0.230 0.260 0.213 0.238 0.249 0.380 0.254 154666000 154219000 447000 114313000 113869000 444000 0 0 700000 100000 4300000 600000 0 4687000 14764000 3758000 13191000 3800000 8384000 5171000 15686000 15686000 0 0 0 0 15686000 15686000 5420000 5420000 0 0 0 0 5420000 5420000 7302000 249000 -24085000 -561000 -18650000 -69844000 -16345000 17954000 -12874000 -53373000 0 0 0 0 0 0 0 0 0 1161000 3465000 2643000 5953000 513000 1460000 1004000 2892000 183470000 138698000 6300000 62051000 94073000 231828000 194285000 5861000 45658000 50000000 75000000 0.0075 44900000 0 44911000 5400000 -5821000 29686000 39593000 -1912000 -14114000 -15515000 0 0 0 0 10500000 4300000 1 -4687000 -14764000 -3758000 -13191000 296000 316000 327000 327000 800000 3630000 3504000 300000 -2405000 -1746000 -379000 -219000 17741000 16933000 5389000 0 0 5696000 437000 175000 34841000 8200000 6200000 11000000 5500000 8600000 17200000 4800000 14500000 6200000 8000000 22100000 9700000 5400000 8000000 12000000 2000000 2400000 1500000 2100000 2500000 1800000 11851000 18733000 0 73000 0 0.10 0.10 1000000 1000000 0 0 2109000 3691000 1741000 0 7800000 58600000 600000 15500000 600000 700000 73854000 16604000 5000 12000 44300000 0 50000000 35386000 10268000 -24085000 -561000 -18650000 -69844000 -69844000 1873000 1626000 0 14455000 14500000 6336000 6336000 0 0 6336000 6336000 6336000 0 0 6336000 3000000 -626904000 -696748000 26000000 P4Y 0 1000 6000 3000 0 7000 12000 35000 78000 8000 12000 0 9.83 9.83 19.95 19.95 P8Y 4000 0 21573000 21573000 1209000 1161000 44000 4000 -826000 -826000 -800000 -40000 -917000 877000 12000 -48000 60000 25000000.0 14600000 400000 5400000 169777000 -431000 816016000 2157000 -626904000 -21061000 100212000 -104000 815031000 2157000 -696748000 -20124000 3881 0 0 3881 0 3881000 1209000 1169000 21061000 20124000 20387000 20390000 20455000 20416000 20387000 20390000 20455000 20416000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s active partner companies were as follows as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Partner Company</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safeguard&#160;Primary&#160;Ownership&#160;as&#160;of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting&#160;Method</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AdvantEdge Healthcare Solutions, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aktana, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Apprenda, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Brickwork</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cask Data, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CloudMine, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clutch Holdings, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full Measure Education, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hoopla Software, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">InfoBionic, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lumesis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MediaMath, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">meQuilibrium</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moxe Health Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NovaSom, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prognos (fka Medivo, Inc.)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Propeller Health, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QuanticMind, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sonobi, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spongecell, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Syapse, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">T-REX Group, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transactis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trice Medical, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WebLinc, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zipnosis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding options that vest based on </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> different types of vesting schedules:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:92%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance-based;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">service-based.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Cash Equivalents</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash equivalents consist of certificates of deposit with various maturity dates. Amounts included in restricted cash equivalents represent those required to be set aside by a contractual agreement with a bank as collateral for a letter of credit. The restriction on the cash will lapse when the related letter of credit is terminated or expires.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its partner companies are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not have a material adverse effect on the Company&#8217;s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company&#8217;s consolidated financial position and results of operations or that of its partner companies. The Company records costs associated with legal fees as such services are rendered.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had outstanding guarantees of </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> which related to one of the Company's private equity holdings. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to return a portion or all the distributions it received as a general partner of a private equity fund for further distribution to such fund's limited partners (&#8220;clawback&#8221;). The Company&#8217;s ownership in the fund is </font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;">. The clawback liability is joint and several, such that the Company may be required to fund the clawback for other general partners should they default. The Company believes its potential liability due to the possibility of default by other general partners is remote. The Company was notified by the fund's manager that the fund is being dissolved and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's clawback liability was paid in the first quarter of 2017. The maximum additional clawback liability is </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> which was reflected in Other long-term liabilities on the Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2001, the Company entered into an agreement with a former Chairman and Chief Executive Officer of the Company, to provide for annual payments of </font><font style="font-family:inherit;font-size:10pt;">$0.65 million</font><font style="font-family:inherit;font-size:10pt;"> per year and certain health care and other benefits for life. The related current liability of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> was included in Accrued expenses and other current liabilities and the long-term portion of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> was included in Other long-term liabilities on the Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provided a </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;"> letter of credit that is scheduled to expire on March&#160;31, 2019 to the landlord of CompuCom Systems, Inc.&#8217;s Dallas headquarters as required in connection with the sale of CompuCom Systems in 2004. The letter of credit is secured by cash which is classified as Long-term restricted cash equivalents on the Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for &#8220;good reason.&#8221; The maximum aggregate exposure under the agreements was approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company's former partner company, Advanced BioHealing, Inc. (&#8220;ABH&#8221;) was acquired by Shire plc (&#8220;Shire&#8221;).&#160; Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (&#8220;DOJ&#8221;) false claims act investigation relating to ABH (the &#8220;Investigation&#8221;).&#160;In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (&#8220;CID&#8221;) from the DOJ regarding ABH and Safeguard&#8217;s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.&#160; To the Company&#8217;s knowledge, the CID was related to multiple qui tam (&#8220;whistleblower&#8221;) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company&#8217;s employees along with other entities and individuals as defendants.&#160; At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH recently entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions of Ownership Interests in Partner Companies</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September, August, March and February 2017, the Company funded an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> of convertible bridge loans to InfoBionic, Inc. The Company had previously deployed an aggregate of $</font><font style="font-family:inherit;font-size:10pt;">14.5 million</font><font style="font-family:inherit;font-size:10pt;"> in InfoBionic. InfoBionic is an emerging digital health company focused on creating patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. The Company accounts for its interest in InfoBionic under the equity method. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September, July and June 2017, the Company funded an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> of convertible bridge loans to Cask Data, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;"> in Cask Data. Cask Data makes building and running big data solutions on-premises or in the cloud easy with Cask Data Application Platform. The Company accounts for its interest in Cask Data under the equity method.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, the Company deployed </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> into meQuilibrium. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in meQuilibrium. meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being. The Company accounts for its interest in meQuilibrium under the equity method. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the Company funded </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of convertible bridge loans to Hoopla Software, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> in Hoopla Software. Hoopla Software provides cloud-based software that helps sales organizations inspire and motivate sales team performance. The Company accounts for its interest in Hoopla Software under the equity method.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August, June and February 2017, the Company funded an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> of convertible loans to NovaSom, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;"> in NovaSom. NovaSom is a medical device company focused on obstructive sleep apnea, specifically home testing with its FDA-cleared wireless device called AccuSom</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> home sleep test. The Company accounts for its interest in NovaSom under the equity method.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company deployed </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> into QuanticMind, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$9.7 million</font><font style="font-family:inherit;font-size:10pt;"> in QuanticMind. QuanticMind delivers the most intelligent, scalable and fastest platform for maximizing digital marketing performance, including paid search and social, for enterprises. The Company accounts for its interest in QuanticMind under the equity method. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June and April 2017, the Company funded an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> of a convertible bridge loan to Sonobi, Inc. The Company had previously deployed </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> in Sonobi. Sonobi is an advertising technology developer that designs advertising tools and solutions for the industry's leading media, publishers, brand advertisers, media agencies, DSPs, and media technology providers. The Company accounts for its interest in Sonobi under the equity method. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June and January 2017, the Company funded an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> of convertible bridge loans to WebLinc, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;"> in WebLinc. WebLinc is a commerce platform and services provider for fast growing online retailers. The Company accounts for its interest in WebLinc under the equity method.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, the Company funded </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> of a convertible bridge loan to Good Start Genetics, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$17.2 million</font><font style="font-family:inherit;font-size:10pt;"> in Good Start Genetics. Good Start Genetics was acquired by Invitae Corporation in August 2017. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Company deployed </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> into Trice Medical, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in Trice Medical. Trice Medical is a diagnostics company focused on micro invasive technologies. The Company accounts for its interest in Trice Medical under the equity method. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, the Company deployed </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> into Aktana, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;"> in Aktana. Aktana leverages big data and machine learning to enable pharmaceutical brands to dynamically optimize their strategy and enhance sales execution. The Company accounts for its interest in Aktana under the equity method.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March and January 2017, the Company deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> into CloudMine, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> in CloudMine. CloudMine empowers payers, providers, and pharmaceutical organizations to mobilize patient information by building robust applications and driving actionable insights. The Company accounts for its interest in CloudMine under the equity method.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company funded </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of a bridge loan to Lumesis, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;"> in Lumesis. Lumesis is a financial technology company focused on providing business efficiency, regulatory and data solutions to the municipal bond marketplace. The Company accounts for its interest in Lumesis under the equity method.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company deployed </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> into Full Measure Education, Inc. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;"> in Full Measure. Full Measure designs next-generation, mobile-first technologies for colleges throughout the United States. The Company accounts for its interest in Full Measure under the equity method.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company funded </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of a convertible bridge loan to Aventura, Inc. to fund wind-down activities. The Company had previously deployed an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;"> in Aventura. The adjusted carrying value of the Company's interest in Aventura was </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> at September 30, 2017. The Company accounted for its interest in Aventura under the equity method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,879</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">806</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s option awards to employees was estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate was based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected term of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility measured using weekly price observations of the Company&#8217;s common stock for a period equal to the stock option&#8217;s expected term.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding options that vest based on </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> different types of vesting schedules:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:92%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance-based;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">service-based.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company&#8217;s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. During the nine months ended September 30, 2017 and 2016, the Company did not issue any performance-based options to employees. During the nine months ended September 30, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;">0 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4 thousand</font><font style="font-family:inherit;font-size:10pt;"> performance-based options vested, respectively. During the nine months ended September 30, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;">8 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">35 thousand</font><font style="font-family:inherit;font-size:10pt;"> performance-based options were canceled or forfeited. The Company recorded compensation expense related to performance-based options of </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended September 30, 2017 and a reduction in compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended September 30, 2017. The Company recorded compensation expense related to performance-based options of </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and nine months ended September 30, 2016, respectively. The maximum number of unvested options at September 30, 2017 attainable under these grants was </font><font style="font-family:inherit;font-size:10pt;">284 thousand</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service-based options generally vest over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> years after the date of grant and expire </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">eight</font><font style="font-family:inherit;font-size:10pt;"> years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based options is the period over which the award vests. During the nine months ended September 30, 2017 and 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">0 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12 thousand</font><font style="font-family:inherit;font-size:10pt;"> service-based options, respectively, to employees. During the nine months ended September 30, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;">78 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">12 thousand</font><font style="font-family:inherit;font-size:10pt;"> service-based options, respectively, were canceled or forfeited. The Company recorded compensation expense related to service-based options of </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and nine months ended September 30, 2017, respectively. The Company recorded compensation expense related to service-based options of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and nine months ended September 30, 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance-based stock units vest based on achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies, as described above related to performance-based awards. Performance-based stock units represent the right to receive shares of the Company&#8217;s common stock, on a one-for-one basis. During the nine months ended September 30, 2017 and 2016, the Company did not issue any performance-based stock units to employees and no performance-based stock units vested. During the nine months ended September 30, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;">6 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">0 thousand</font><font style="font-family:inherit;font-size:10pt;"> performance-based stock units were canceled or forfeited. Under the terms of the 2016, 2015 and 2014 performance-based awards, once performance-based stock units are fully vested, participants are entitled to receive cash payments based on their initial performance grant values as target capital returns are exceeded. At September 30, 2017, the liability associated with such potential cash payments was </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September 30, 2017 and 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">50 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">43 thousand</font><font style="font-family:inherit;font-size:10pt;"> deferred stock units, respectively, to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in lieu of directors fees are </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> vested at the grant date; matching deferred stock units equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> of directors&#8217; fees deferred vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> year following the grant date or, if earlier, upon reaching age </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">65</font><font style="font-family:inherit;font-size:10pt;">. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of employment or service, death or permanent disability.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September 30, 2017 and 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">7 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">0 thousand</font><font style="font-family:inherit;font-size:10pt;"> restricted stock awards, respectively, and </font><font style="font-family:inherit;font-size:10pt;">3 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1 thousand</font><font style="font-family:inherit;font-size:10pt;"> restricted stock awards were canceled or forfeited, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total compensation expense for performance-based stock units, deferred stock units, and restricted stock was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended September 30, 2017 and 2016, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended September 30, 2017 and 2016, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income (Loss) Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The calculations of net income (loss) per share were as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In&#160;thousands,&#160;except&#160;per&#160;share&#160;data)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,650</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,085</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diluted:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,650</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,085</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for dilutive share computation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a consolidated or equity method partner company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the partner company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted earnings per share for the three and nine months ended September 30, 2017 and 2016 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:9px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At September 30, 2017 and 2016, options to purchase </font><font style="font-family:inherit;font-size:10pt;">0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, at prices ranging from </font><font style="font-family:inherit;font-size:10pt;">$9.83</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$19.95</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9.83</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$19.95</font><font style="font-family:inherit;font-size:10pt;">, respectively, were excluded from the calculations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:9px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At September 30, 2017 and 2016, unvested restricted stock, performance-based stock units and DSUs convertible into </font><font style="font-family:inherit;font-size:10pt;">0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">0.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares of stock, respectively, were excluded from the calculations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:9px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At September 30, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock representing the effect of the assumed conversion of the 2018 Debentures, were excluded from the calculations.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial instruments recorded at fair value on the Company&#8217;s Consolidated Balance Sheets are categorized as follows:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Include other inputs that are directly or indirectly observable in the marketplace.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs which are supported by little or no market activity.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash equivalents</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities&#8212;held-to-maturity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities&#8212;held-to-maturity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> of marketable securities had contractual maturities which were less than one year and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of marketable securities had contractual maturities greater than one year. Certificates of deposit are classified as held-to-maturity securities carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1 inputs under the fair value hierarchy. Trading securities consist of </font><font style="font-family:inherit;font-size:10pt;">414,237</font><font style="font-family:inherit;font-size:10pt;"> shares of Invitae Corporation common shares obtained in connection with the sale of Good Start Genetics. The trading securities are carried at fair value based on the closing stock price on the last trading day of the reporting period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated income tax benefit (expense) was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and nine months ended September 30, 2017 and 2016. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in the three and nine months ended September 30, 2017 was offset by changes in the valuation allowance. The tax expense that would have been recognized in the three and nine months ended September 30, 2016 was offset by changes in the valuation allowance. During the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had no material changes in uncertain tax positions.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ownership Interests in and Advances to Partner Companies</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the carrying value of the Company&#8217;s ownership interests in and advances to partner companies.&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity Method:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner companies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private equity funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost Method:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other holdings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private equity funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,096</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advances to partner companies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, Good Start Genetics, Inc. was acquired by Invitae Corporation ("Invitae"). The Company received </font><font style="font-family:inherit;font-size:10pt;">414,237</font><font style="font-family:inherit;font-size:10pt;"> shares of Invitae common stock worth </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> on the closing date in connection with the transaction, excluding </font><font style="font-family:inherit;font-size:10pt;">137,125</font><font style="font-family:inherit;font-size:10pt;"> shares of Invitae common stock worth </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> on the closing date which will be held in escrow until August 2018. The Company recognized a gain of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> on the transaction, which is included in Equity income (loss) in the Consolidated Statements of Operations for the three and nine months ended September 30, 2017. The Invitae shares are classified as Trading securities and recorded at fair value on the Consolidated Balance Sheet at September 30, 2017. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company sold its interest in partner company Nexxt, Inc., formerly Beyond.com, back to Nexxt, Inc. for </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company received </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year, </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> note for the balance due, which accrues interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum. The receipt of the </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash resulted in a gain of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> note is fully reserved and has a carrying value of zero as of September 30, 2017. A gain will be recorded when the note is repaid. Interest is payable annually and interest income is recorded as earned throughout the year. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2017, the Company recognized an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> related to Spongecell, Inc. which is reflected in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The impairment was based on the value at which the Company expects Spongecell to raise its next financing round. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first and second quarters of 2017, the Company recognized impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to Pneuron, Inc. which is reflected in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The impairments were due to a decline in revenue and an inability to attract third party investors or acquirers. Pneuron has ceased business operations and the adjusted carrying value of the Company's interest in Pneuron is </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> at September 30, 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, Putney, Inc. was acquired by Dechra Pharmaceuticals Plc. The Company received </font><font style="font-family:inherit;font-size:10pt;">$58.6 million</font><font style="font-family:inherit;font-size:10pt;"> in cash proceeds in connection with the transaction. In April 2017, the Company received an additional </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with the expiration of the final escrow period resulting in a gain of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, Quantia, Inc. was acquired by Physicians Interactive. The Company received </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> in initial cash proceeds in connection with the transaction in July 2015 and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with the expiration of the initial escrow period in July 2016. In January 2017, the Company received an additional </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with the expiration of the final escrow period resulting in a gain of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Debentures</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> secured, revolving credit facility (&#8220;Credit Facility&#8221;) with HPS Investment Partners, LLC (&#8220;Lender&#8221;). At closing, the Company borrowed </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">, which resulted in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$44.3 million</font><font style="font-family:inherit;font-size:10pt;"> after closing fees to the Lender and other third parties. The Credit Facility has a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year term with a scheduled maturity of May 11, 2020 and bears interest at a rate of either: (A) LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">8.5%</font><font style="font-family:inherit;font-size:10pt;"> (subject to a LIBOR floor of </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">), payable on the last day of the one, two or three month interest period applicable to the LIBOR rate advance, or (B) </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> plus the greater of: </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">; the Federal Funds Rate plus </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;">; LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">; or the U.S. Prime Rate, payable monthly in arrears. The Credit Facility is not amortized and interest payable under the Credit Facility will reflect at least </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> as being drawn and outstanding at all times during the term. The Credit Facility also includes an unused line fee equal to </font><font style="font-family:inherit;font-size:10pt;">0.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum of the average unused portion of the Credit Facility and a loan service fee, both paid quarterly. The Credit Facility is secured by all of the Company's assets in accordance with the terms of the Credit Facility. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Facility requires the Company to maintain (i) a liquidity threshold of at least </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash of at least </font><font style="font-family:inherit;font-size:10pt;">1.75</font><font style="font-family:inherit;font-size:10pt;">x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of the Company&#8217;s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold of at least </font><font style="font-family:inherit;font-size:10pt;">$350 million</font><font style="font-family:inherit;font-size:10pt;">; and (iv) certain diversification requirements and concentration limits with respect to the Company&#8217;s capital deployments to its partner companies. Subject to customary exclusions, the Lender has the right to have one observer representative attend meetings of the Company's Board of Directors. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Facility provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, nonpayment of principal or interest; non-compliance with debt covenants; defaults in, or failure to pay, certain other indebtedness; the rendering of judgments to pay certain amounts of money; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is not cured within the time periods specified (if any), the Lender may declare the outstanding amount under the Credit Facility to be immediately due and payable. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At September&#160;30, 2017, the principal amount outstanding under the Credit Facility was </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">, the unamortized discount and debt issuance costs were </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> and the net carrying value of the credit facility was $</font><font style="font-family:inherit;font-size:10pt;">44.9 million</font><font style="font-family:inherit;font-size:10pt;">. The Company is amortizing the excess of the principal amount of the Credit Facility over its carrying value over the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year term as additional interest expense using the effective interest method and recorded </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of such expense for the three and nine months ended September 30, 2017. The effective interest rate on the Credit Facility is </font><font style="font-family:inherit;font-size:10pt;">14.5%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Debentures</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2012, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount of its </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior debentures due on May 15, 2018 (the &#8220;2018 Debentures&#8221;). The 2018 Debentures may be settled in cash or partially in cash upon conversion. Accordingly, the Company separately accounts for the liability and equity components of the 2018 Debentures. The carrying amount of the liability component was determined at the transaction date by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component represented by the embedded conversion option was determined by deducting the fair value of the liability component from the initial proceeds of the 2018 Debentures as a whole. </font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July and June 2017, the Company repurchased on the open market, and retired, an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> face value of the 2018 Debentures at a cost of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">, including transaction fees. In connection with the repurchase of these 2018 Debentures, the Company recognized a </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> reduction in equity which is included in Accumulated Paid-In Capital in the Consolidated Balance Sheet as of September 30, 2017 and a </font><font style="font-family:inherit;font-size:10pt;">$29 thousand</font><font style="font-family:inherit;font-size:10pt;"> loss on extinguishment of the liability which is included in Other loss in the Consolidated Statements of Operations for the nine months ended September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the carrying amount of the equity component was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;">, the principal amount of the liability component was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;">, the unamortized discount and debt issuance costs were </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and the net carrying value of the liability component was </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">. The Company is amortizing the excess of the face value of the 2018 Debentures over their carrying value over their term as additional interest expense using the effective interest method and recorded </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of such expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The effective interest rate on the 2018 Debentures is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.7%</font><font style="font-family:inherit;font-size:10pt;">. At September&#160;30, 2017, the fair value of the </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;"> outstanding 2018 Debentures was approximately </font><font style="font-family:inherit;font-size:10pt;">$42.2 million</font><font style="font-family:inherit;font-size:10pt;">, based on the midpoint of the bid and ask prices as of such date. The Company anticipates repaying or refinancing the outstanding 2018 Debentures by the maturity date of May 15, 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Accounting Standards Update No. 2014-09</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">("ASU 2014-09"). ASU 2014-09 and related subsequent amendments outline a single comprehensive model to use to account for revenue arising from contracts with customers and supersede most current revenue recognition guidance. For public companies, the guidance is effective for annual periods beginning after December 15, 2017 and any interim periods that fall within that reporting period. For nonpublic companies, the guidance is effective for annual periods beginning after December 15, 2018 and interim periods within annual periods beginning after December 15, 2019 with early adoption permitted. As the new standard will supersede most existing revenue guidance, it could impact revenue and cost recognition for partner companies. Any change in revenue or cost recognition for partner companies could affect the Company's recognition of its share of the results of its equity method partner companies. The Company has been closely monitoring the FASB and SEC activity related to the new standard.&#160; On July 20, 2017, the SEC staff observer at the FASB&#8217;s Emerging Issues Task Force ("EITF") meeting announced that the SEC staff will not object if a private company equity method investee meeting the definition of a public business entity that otherwise would not meet the definition of a public business entity except for the inclusion of its financial statements or financial information in another entity&#8217;s filings with the SEC, uses private company adoption dates for the new revenue standard.&#160; As a result, the Company anticipates that its private, calendar year partner companies will adopt the new revenue standard for the year ending December 31, 2019.&#160; The impact of adoption of the new revenue standard will be reflected in the Company&#8217;s financial results for the interim and annual reporting periods beginning in 2020 on a one quarter-lag basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (&#8220;Safeguard&#8221; or the &#8220;Company&#8221;) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company&#8217;s Consolidated Financial Statements and Notes thereto included in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$34.3 million</font><font style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents and </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> of marketable securities for a total of </font><font style="font-family:inherit;font-size:10pt;">$39.7 million</font><font style="font-family:inherit;font-size:10pt;">. As of September 30, 2017, the Company had </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;"> of principal outstanding on its convertible senior notes, which the Company anticipates repaying or refinancing by the maturity date of May 15, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> secured, revolving credit facility (&#8220;Credit Facility&#8221;) with HPS Investment Partners, LLC (&#8220;Lender&#8221;). As of September 30, 2017, the Company had </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> of principal outstanding on the Credit Facility due in May 2020. The Credit Facility requires the Company to maintain (i) a liquidity threshold of at least </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash, of at least </font><font style="font-family:inherit;font-size:10pt;">1.75</font><font style="font-family:inherit;font-size:10pt;">x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of the Company&#8217;s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold, of at least </font><font style="font-family:inherit;font-size:10pt;">$350 million</font><font style="font-family:inherit;font-size:10pt;">; and (iv) certain diversification requirements and concentration limits with respect to the Company&#8217;s capital deployments to its partner companies. As of the date these consolidated financial statements were issued, the Company was in compliance with all of these covenants. </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company funds its operations with cash and marketable securities on hand as well as proceeds from the sales of its interest in its partner companies. Due to the nature of the mergers and acquisitions market, and the developmental cycle of companies like the Company&#8217;s partner companies, the Company&#8217;s ability to generate specific amounts of liquidity from sales of its partner company interests in any given period of time cannot be assured. Accordingly, the forecasts which the Company utilizes for projecting future compliance with covenants related to its Credit Facility include significantly discounted probability-weighted proceeds from the sales of its interests in its partner companies. Based on these forecasts, management believes the Company will continue to remain in compliance with all of its debt covenants. Management's plans to remain in compliance with these covenants include selling certain of its partner company interests in the ordinary course of its business and limiting capital deployments to new and existing partner companies. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compliance with any of the covenants would constitute an event of default under the Credit Facility, and the Lender could choose to accelerate the maturity of the indebtedness. If the Lender were to accelerate the maturity of the indebtedness, the Company may not have sufficient immediate liquidity to repay the entire balance of its outstanding borrowings and other obligations under the Credit Facility. Should the Company not be in compliance with any of its debt covenants and be unable to obtain waivers for such events of default, management would pursue one of a number of potential alternatives to satisfy the obligations, including completing an equity offering or obtaining a new debt facility to refinance its existing debt. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Cash Equivalents</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash equivalents consist of certificates of deposit with various maturity dates. Amounts included in restricted cash equivalents represent those required to be set aside by a contractual agreement with a bank as collateral for a letter of credit. The restriction on the cash will lapse when the related letter of credit is terminated or expires. The letter of credit is scheduled to expire on March 31, 2019. The following table provides a reconciliation of cash, cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In thousands)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Accounting Standards Update No. 2014-09</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">("ASU 2014-09"). ASU 2014-09 and related subsequent amendments outline a single comprehensive model to use to account for revenue arising from contracts with customers and supersede most current revenue recognition guidance. For public companies, the guidance is effective for annual periods beginning after December 15, 2017 and any interim periods that fall within that reporting period. For nonpublic companies, the guidance is effective for annual periods beginning after December 15, 2018 and interim periods within annual periods beginning after December 15, 2019 with early adoption permitted. As the new standard will supersede most existing revenue guidance, it could impact revenue and cost recognition for partner companies. Any change in revenue or cost recognition for partner companies could affect the Company's recognition of its share of the results of its equity method partner companies. The Company has been closely monitoring the FASB and SEC activity related to the new standard.&#160; On July 20, 2017, the SEC staff observer at the FASB&#8217;s Emerging Issues Task Force ("EITF") meeting announced that the SEC staff will not object if a private company equity method investee meeting the definition of a public business entity that otherwise would not meet the definition of a public business entity except for the inclusion of its financial statements or financial information in another entity&#8217;s filings with the SEC, uses private company adoption dates for the new revenue standard.&#160; As a result, the Company anticipates that its private, calendar year partner companies will adopt the new revenue standard for the year ending December 31, 2019.&#160; The impact of adoption of the new revenue standard will be reflected in the Company&#8217;s financial results for the interim and annual reporting periods beginning in 2020 on a one quarter-lag basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In thousands)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The calculations of net income (loss) per share were as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In&#160;thousands,&#160;except&#160;per&#160;share&#160;data)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,650</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,085</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diluted:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,650</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,085</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for dilutive share computation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash equivalents</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities&#8212;held-to-maturity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement at December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities&#8212;held-to-maturity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the carrying value of the Company&#8217;s ownership interests in and advances to partner companies.&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity Method:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner companies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private equity funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost Method:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other holdings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private equity funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,096</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advances to partner companies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited - In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,879</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">806</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment based upon the similar nature of its technology-driven partner companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company held interests in </font><font style="font-family:inherit;font-size:10pt;">26</font><font style="font-family:inherit;font-size:10pt;"> non-consolidated partner companies. The Company&#8217;s active partner companies were as follows as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Partner Company</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safeguard&#160;Primary&#160;Ownership&#160;as&#160;of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting&#160;Method</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AdvantEdge Healthcare Solutions, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aktana, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Apprenda, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Brickwork</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cask Data, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CloudMine, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clutch Holdings, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full Measure Education, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hoopla Software, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">InfoBionic, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lumesis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MediaMath, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">meQuilibrium</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moxe Health Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NovaSom, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prognos (fka Medivo, Inc.)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Propeller Health, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QuanticMind, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sonobi, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spongecell, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Syapse, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">T-REX Group, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transactis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trice Medical, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WebLinc, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zipnosis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s assets were located in the United States.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;of the Company's outstanding common stock. During the nine months ended September 30, 2016, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">0.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares at an aggregate cost of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> with </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;"> remaining for repurchase under the existing authorization.</font></div></div> EX-101.SCH 7 sfe-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Acquisitions of Ownership Interests in Partner Companies and Funds link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Acquisitions of Ownership Interests in Partner Companies and Funds (Detail) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Commitments and Contingencies (Detail) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statement link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Credit Facility and Convertible Debentures link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Credit Facility and Convertible Debentures - Convertible Senior Debentures Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Credit Facility and Convertible Debentures - Credit Arrangements Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2420401 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements - Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Fair Value Measurements - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - General General (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - General General (Tables) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - General Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Net Income (Loss) Per Share - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds - Carrying Value (Detail) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Segment Reporting - Active Partner Companies by Segment (Detail) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Segment Reporting - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Stock-Based Compensation - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 sfe-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 sfe-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 sfe-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Earnings Per Share [Abstract] Basic: Earnings Per Share, Basic [Abstract] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Net income (loss) per share (in dollars per share) Earnings Per Share, Basic Diluted: Earnings Per Share, Diluted [Abstract] Weighted average common shares outstanding Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Net loss for dilutive share computation Net Income (Loss) Attributable to Parent, Diluted Net Income (Loss) Per Share Earnings Per Share [Text Block] Debt Disclosure [Abstract] Credit Facility and Convertible Debentures Long-term Debt [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Segment Reporting [Abstract] Segment Reporting Segment Reporting Disclosure [Text Block] Accounting Policies [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Debt Convertible Debt [Member] Line of Credit Line of Credit [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Marketable Securities Cash, cash equivalents, and marketable securities Cash Cash Equivalents And Marketable Securities Cash, cash equivalents and marketable securities. Principal amount outstanding Debt Instrument, Convertible, Principal Amount Outstanding Debt Instrument, Convertible, Principal Amount Outstanding Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Debt instrument, face amount Long-term Debt, Gross Liquidity threshold Debt Instrument, Debt Covenants, Liquidity Threshold Debt Instrument, Debt Covenants, Liquidity Threshold Unrestricted cash multiplier Debt Instrument, Debt Covenants, Tangible Net Worth Plus Unrestricted Cash Multiplier Debt Instrument, Debt Covenants, Tangible Net Worth Plus Unrestricted Cash Multiplier Minimum aggregate appraised value plus liquidity threshold Debt Instrument, Debt Covenants, Minimum Aggregate Appraised Value Plus Liquidity Threshold Debt Instrument, Debt Covenants, Minimum Aggregate Appraised Value Plus Liquidity Threshold Cash and cash equivalents Long-term restricted cash equivalents Restricted Cash and Cash Equivalents, Noncurrent Total cash, cash equivalents and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Calculations of Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitment Contingencies And Guarantees [Table] Commitment Contingencies And Guarantees [Table] Commitment Contingencies And Guarantees [Table] Investment [Axis] Investment [Axis] Investment [Domain] Investment [Domain] Private equity funds Private Equity Funds [Member] Contingent Consideration by Type Contingent Consideration by Type [Axis] Contingent Consideration Type Contingent Consideration Type [Domain] Clawback Liability Clawback Liability [Member] Clawback liability. Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued expenses and other current liabilities. Other long-term liabilities Other Long Term Liabilities [Member] Other long term liabilities. Letter of credit Letter of Credit [Member] Restructuring Type Restructuring Type [Axis] Type of Restructuring Type of Restructuring [Domain] Employee Severance Employee Severance [Member] Commitment Contingencies And Guarantees [Line Items] Commitment Contingencies And Guarantees [Line Items] Commitment Contingencies And Guarantees [Line Items] Company outstanding guarantees Guarantor Obligations, Maximum Exposure, Undiscounted Accrued expenses Accrued Liabilities, Current Other long-term liabilities Other Liabilities, Noncurrent Company's ownership in the funds Company Ownership In Funds Company's ownership in the funds. Clawback Liability Paid Clawback Liability Paid Clawback Liability Paid Annual payments Future Annual Payment To Chairman And Chief Executive Officer Future annual payment to former chairman and chief executive officer. Liability to former chairman and chief executive officer, current Other Deferred Compensation Arrangements, Liability, Current Liability to former chairman and chief executive officer, non-current Deferred Compensation Liability, Classified, Noncurrent Letter of credit under the credit facility Letters of Credit Outstanding, Amount Maximum severance payments Restructuring and Related Cost, Expected Cost Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Good Start Genetics, Inc. Good Start Genetics Inc [Member] Good start genetics, inc. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Marketable securities, current Held-to-maturity Securities, Current Marketable securities, non current Held-to-maturity Securities, Noncurrent Number of shares received (in shares) Noncash or Part Noncash Divestiture, Number of Shares Received Noncash or Part Noncash Divestiture, Number of Shares Received Income tax benefit (expense) Income Tax Expense (Benefit) Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current Assets: Assets, Current [Abstract] Marketable securities Trading securities Trading Securities Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Ownership interests in and advances to partner companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Long-term marketable securities Other assets Other Assets, Noncurrent Total Assets Assets LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Current Liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation and benefits Employee-related Liabilities, Current Accrued expenses and other current liabilities Convertible senior debentures - current Convertible Debt, Current Total current liabilities Liabilities, Current Credit facility Long-term Line of Credit, Noncurrent Convertible senior debentures Convertible Debt, Noncurrent Total Liabilities Liabilities Commitments and contingencies Commitments and Contingencies Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.10 par value; 1,000 shares authorized Preferred Stock, Value, Issued Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued at September 30, 2017 and December 31, 2016 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Treasury stock, at cost; 1,161 and 1,209 shares at September 30, 2017 and December 31, 2016, respectively Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total Liabilities and Equity Liabilities and Equity Document Documentand Entity Information [Abstract] Document Documentand Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Trading Symbol Trading Symbol Active Partner Companies by Segment Schedule Of Company Active Partner [Table Text Block] Schedule Of Company Active Partner [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General And Administrative Expenses General And Administrative Expenses [Member] General And Administrative Expenses [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Number of operating segments Number of Operating Segments Non-consolidated partner companies Partner Companies Not Consolidated In Financial Statements Partner Companies Not Consolidated In Financial Statements. Investments in and Advances to Affiliates, Schedule of Investments [Abstract] Ownership Interests in and Advances to Partner Companies Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options Employee Stock Option [Member] Deferred stock units, performance-based stock units and restricted stock Restricted Stock Unit And Performance Stock Unit And Deferred Stock Unit [Member] Restricted stock unit and performance stock unit and deferred stock unit. Convertible Senior Debentures due 2018 Convertible Senior Debentures Due Two Thousand Eighteen [Member] Convertible Senior Debentures Due Two Thousand Eighteen [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Share of common stock excluded from diluted net loss per share calculation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares of common stock at prices ranging, lower limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Shares of common stock at prices ranging, upper limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Equity [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Stock repurchased during period, value Stock Repurchased During Period, Value Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Equity Method Investments and Joint Ventures [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] InfoBionic InfoBionic [Member] InfoBionic [Member] Cask Data Cask Data [Member] Cask Data [Member] meQuilibrium meQuilibrium [Member] meQuilibrium [Member] Hoopla Software, Inc. Hoopla Software Inc [Member] Hoopla software inc member. Novasom, Inc. Nova Som Inc [Member] NovaSom inc. QuanticMind QuanticMind [Member] QuanticMind [Member] Sonobi Sonobi [Member] Sonobi [Member] WebLinc WebLinc [Member] WebLinc [Member] Trice Medical, Inc. Trice [Member] Trice [Member] Aktana, Inc. Aktana, Inc. [Member] Aktana, Inc. [Member] CloudMine CloudMine [Member] CloudMine [Member] Lumesis, Inc. Lumesis Inc [Member] Lumesis Inc. Full Measure Full Measure [Member] Full Measure [Member] Aventura Aventura [Member] Aventura [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Payments to acquire equity method investments Payments to Acquire Equity Method Investments Equity method investments Equity Method Investments Convertible bridge loan Convertible Bridge Loan Convertible bridge loan. Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Proceeds from sales of and distributions from companies Proceeds from Divestiture of Businesses and Interests in Affiliates Acquisitions of ownership interests in companies Advances and loans to companies Payments for Advance to Affiliate Repayment of advances and loans to companies Proceeds from Collection of Advance to Affiliate Increase in marketable securities Payments to Acquire Held-to-maturity Securities Decrease in marketable securities Proceeds from Sale and Maturity of Held-to-maturity Securities Capital expenditures Payments to Acquire Productive Assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash Flows from Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from credit facility Proceeds from Lines of Credit Issuance costs of credit facility Payments of Debt Issuance Costs Repurchase of convertible senior debentures Repayments of Convertible Debt Issuance of Company common stock, net Proceeds from Issuance of Common Stock Tax withholdings related to equity-based awards Payments Related to Tax Withholding for Share-based Compensation Repurchase of Company common stock Payments for Repurchase of Common Stock Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash, cash equivalents and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash equivalents at beginning of period Cash, cash equivalents and restricted cash equivalents at end of period Investments, All Other Investments [Abstract] Investment [Table] Investment [Table] Pneuron Pneuron [Member] Pneuron [Member] Putney Inc Putney Inc [Member] Putney inc. Beyond.com, Inc Beyond Com Inc [Member] Beyond com Inc. Quantia, Inc. Quantia Inc. [Member] Quantia Inc. [Member] Spongecell Inc. Spongecell Inc [Member] Spongecell Inc. Investment [Line Items] Investment [Line Items] Amount of consideration received Noncash or Part Noncash Divestiture, Amount of Consideration Received Number of shares received, amount held in escrow (in shares) Noncash or Part Noncash Divestiture, Number of Shares Received, Amount Held in Escrow Noncash or Part Noncash Divestiture, Number of Shares Received, Amount Held in Escrow Amount of consideration received, amount held in escrow Noncash or Part Noncash Divestiture, Amount of Consideration Received, Amount Held in Escrow Noncash or Part Noncash Divestiture, Amount of Consideration Received, Amount Held in Escrow Consideration received per transaction Sale of Stock, Consideration Received Per Transaction Proceeds from sale of business Term of note receivable (in years) Noncash or Part Noncash Divestiture, Term of Note Receivable Noncash or Part Noncash Divestiture, Term of Note Receivable Interest rate on note receivable Noncash or Part Noncash Divestiture, Interest Rate on Note Receivable Noncash or Part Noncash Divestiture, Interest Rate on Note Receivable Gain on sale of business Gain (Loss) on Disposition of Business Asset impairment charges Asset Impairment Charges Acquisitions of Ownership Interests in Partner Companies Cost and Equity Method Investments Disclosure [Text Block] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Reported Value Measurement [Member] Reported Value Measurement [Member] Estimate of Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Eligible Item or Group for Fair Value Option [Axis] Financial Instrument [Axis] Fair Value, Option, Eligible Item or Group [Domain] Financial Instruments [Domain] Certificates of deposit Certificates of Deposit [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Trading securities Trading Liabilities, Fair Value Disclosure Total marketable securities Held-to-maturity Securities, Fair Value Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Performance Shares Performance Shares [Member] Service Based Award Service Based Award [Member] Service based award. Deferred Stock Units Deferred Stock Units [Member] Deferred stock units. Restricted Stock Restricted Stock [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Director Director [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of award vesting types Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types Options vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Options, forfeitures in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Stock-based compensation expense Allocated Share-based Compensation Expense, Net of Tax Stock-based compensation, maximum number of unvested shares (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Maximum Number Of Unvested Shares Share based compensation arrangement by share based payment award equity instruments maximum number of unvested shares. Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Options issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Cancelled in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Cash liability for performance-based units Cash Liability for Performance-Based Units Cash Liability for Performance-Based Units Shares issued to non-employee individual (in shares) Deferred Compensation Arrangement with Individual, Shares Issued Percentage of shares vested in lieu of directors fees at the grant date Percentage Of Shares Vested In Lieu Of Directors Fees At Grant Date Percentage of shares vested in lieu of directors fees at the grant date. Portion of Director fees matched to deferred stock units Portion Of Director Fees Matched To Deferred Stock Units Portion of director fees matched to deferred stock units. Vesting period of deferred stock (in years) Share Based Compensation Arrangement By Share Based Payment Deferred Award Vesting Period Share based compensation arrangement by share based payment deferred award vesting period. Minimum age required for meeting directors fees deferred vest criteria Minimum Age Required For Meeting Directors Fees Deferred Vest Criteria Minimum age required for meeting directors fees deferred vest criteria. Restricted stock granted in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Statement of Comprehensive Income [Abstract] Net loss Share of other comprehensive income of equity method investments Other Comprehensive Income (Loss), Share of Other Comprehensive Income (Loss) of Equity Method Investments Other Comprehensive Income (Loss), Share of Other Comprehensive Income (Loss) of Equity Method Investments Reclassification adjustment for sale of equity method investments Other Comprehensive Income (Loss), Reclassification Adjustment on Sale of Equity Method Investments Other Comprehensive Income (Loss), Reclassification Adjustment on Sale of Equity Method Investments Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Treasury stock Treasury Stock, Shares Restricted Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Investments In And Advances To Affiliates [Table] Investments in and Advances to Affiliates [Table] Partner companies Other Ownership Interest [Member] Investments In And Advances To Affiliates [Line Items] Investments in and Advances to Affiliates [Line Items] Cost method investments Cost Method Investments Advances to partner companies Advances to Affiliate Investments in and advance to affiliates, subsidiaries, associates, and joint ventures Ownership Interests in and Advances to Partner Companies and Private Equity Funds Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] Stock-Based Compensation Expense Schedule of Share-based Compensation, Activity [Table Text Block] Types of Vesting Schedules Schedule of Share-based Payment Award, Types of Vesting Schedules [Table Text Block] Schedule of Share-based Payment Award, Types of Vesting Schedules [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Federal Funds Effective Swap Rate Federal Funds Effective Swap Rate [Member] Interest Rate Application [Axis] Interest Rate Application [Axis] Interest Rate Application [Axis] Interest Rate Application [Domain] Debt Instrument Covenant [Domain] [Domain] for Debt Instrument Covenant [Axis] Interest Rate Application A Interest Rate Application A [Member] Interest Rate Application A [Member] Interest Rate Application B Interest Rate Application B [Member] Interest Rate Application B [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Long-term line of credit outstanding Long-term Line of Credit Debt instrument, term (in years) Debt Instrument, Term Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Interest payable amount outstanding threshold Debt Instrument, Interest Payable Amount Outstanding Threshold Debt Instrument, Interest Payable Amount Outstanding Threshold Commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Long-term debt, gross Unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Long-term debt Long-term Debt Amortization of debt issuance costs Amortization of Debt Issuance Costs Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Debt instrument, face amount Debt Instrument, Face Amount Income Statement [Abstract] General and administrative expense General and Administrative Expense Operating loss Operating Income (Loss) Other loss Other Nonoperating Income (Expense) Interest income Investment Income, Interest Interest expense Interest Expense, Debt Equity income (loss) Income (Loss) from Equity Method Investments Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit (expense) Net loss Net loss per share: Basic (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average shares used in computing loss per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted General Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Additional Paid-in Capital Additional Paid-in Capital [Member] Aggregate face value of convertible senior debentures Interest rate on debentures Debt Instrument, Interest Rate, Stated Percentage Repurchased face amount Debt Instrument, Repurchased Face Amount Repayments of long-term debt Repayments of Long-term Debt Repurchase of convertible senior debentures Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Gross carrying amount of equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Deferred finance costs, noncurrent, net Debt Issuance Costs, Noncurrent, Net Amortization of debt discount (premium) Amortization of Debt Discount (Premium) Fair value of debentures outstanding Debt Instrument, Fair Value Disclosure Business Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Healthcare Healthcare [Member] Healthcare [Member] AdvantEdge Healthcare Solutions, Inc. Advantedge Healthcare Solutions Inc [Member] AdvantEdge Healthcare solutions Inc. Apprenda Apprenda [Member] Apprenda [Member] BrickWork BrickWork [Member] BrickWork [Member] Clutch Holdings, LLC Clutch [Member] Clutch [Member] MediaMath, Inc. Media Math Inc [Member] MediaMath Inc. Moxe Health Moxe Health [Member] Moxe Health [Member] Prognos Prognos [Member] Prognos [Member] Propeller Propeller [Member] Propeller [Member] QuanticMind, Inc. QuanticMind, Inc. [Member] QuanticMind, Inc. [Member] Spongecell Spongecell [Member] Spongecell. Syapse, Inc. Syapse, Inc. [Member] Syapse, Inc. [Member] T-REX Group, Inc. T-REX Group, Inc. [Member] T-REX Group, Inc. [Member] Transactis Transactis [Member] Transactis [Member] Trice Zipnosis Zipnosis [Member] Zipnosis [Member] Ownership interest under equity method, percentage Equity Method Investment, Ownership Percentage Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Accumulated Deficit Retained Earnings [Member] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Treasury Stock Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Balance (in shares) Shares, Issued Balance (in shares) Shares, Outstanding Stock options exercised, net of tax withholdings Stock Issued During Period, Value, Stock Options Exercised Stock options exercised, net of tax withholdings (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of restricted stock, net of tax withholdings Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock, net of tax withholdings (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Repurchase of convertible senior debentures Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Balance Balance (in shares) Balance (in shares) Fair Value Measurements Fair Value Disclosures [Text Block] Equity Stockholders' Equity Note Disclosure [Text Block] Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] EX-101.PRE 11 sfe-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2017
Oct. 24, 2017
Document Documentand Entity Information [Abstract]    
Entity Registrant Name SAFEGUARD SCIENTIFICS INC  
Entity Central Index Key 0000086115  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   20,412,398
Trading Symbol SFE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 34,317 $ 22,058
Marketable securities 5,171 8,384
Trading securities 3,881 0
Prepaid expenses and other current assets 3,691 2,109
Total current assets 47,060 32,551
Property and equipment, net 1,626 1,873
Ownership interests in and advances to partner companies 138,698 183,470
Long-term marketable securities 249 7,302
Long-term restricted cash equivalents 6,336 6,336
Other assets 316 296
Total Assets 194,285 231,828
Current Liabilities:    
Accounts payable 171 140
Accrued compensation and benefits 2,844 3,498
Accrued expenses and other current liabilities 2,495 2,223
Convertible senior debentures - current 40,148 0
Total current liabilities 45,658 5,861
Other long-term liabilities 3,504 3,630
Credit facility 44,911 0
Convertible senior debentures 0 52,560
Total Liabilities 94,073 62,051
Commitments and contingencies
Equity:    
Preferred stock, $0.10 par value; 1,000 shares authorized 0 0
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued at September 30, 2017 and December 31, 2016 2,157 2,157
Additional paid-in capital 815,031 816,016
Treasury stock, at cost; 1,161 and 1,209 shares at September 30, 2017 and December 31, 2016, respectively (20,124) (21,061)
Accumulated deficit (696,748) (626,904)
Accumulated other comprehensive loss (104) (431)
Total Equity 100,212 169,777
Total Liabilities and Equity $ 194,285 $ 231,828
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
shares in Thousands
Sep. 30, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.10 $ 0.10
Preferred stock, shares authorized 1,000 1,000
Common stock, par value $ 0.10 $ 0.10
Common stock, shares authorized 83,333 83,333
Common stock, shares issued 21,573 21,573
Treasury stock 1,169 1,209
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
General and administrative expense $ 3,758 $ 4,687 $ 13,191 $ 14,764
Operating loss (3,758) (4,687) (13,191) (14,764)
Other loss (379) (2,405) (219) (1,746)
Interest income 1,004 513 2,892 1,460
Interest expense (2,643) (1,161) (5,953) (3,465)
Equity income (loss) (12,874) (16,345) (53,373) 17,954
Net loss before income taxes (18,650) (24,085) (69,844) (561)
Income tax benefit (expense) 0 0 0 0
Net loss $ (18,650) $ (24,085) $ (69,844) $ (561)
Net loss per share:        
Basic (in dollars per share) $ (0.91) $ (1.18) $ (3.42) $ (0.03)
Diluted (in dollars per share) $ (0.91) $ (1.18) $ (3.42) $ (0.03)
Weighted average shares used in computing loss per share:        
Basic (in shares) 20,455 20,387 20,416 20,390
Diluted (in shares) 20,455 20,387 20,416 20,390
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash Flows from Operating Activities:    
Net cash used in operating activities $ (15,515) $ (14,114)
Cash Flows from Investing Activities:    
Proceeds from sales of and distributions from companies 16,604 73,854
Acquisitions of ownership interests in companies (11,851) (34,841)
Advances and loans to companies (16,933) (17,741)
Repayment of advances and loans to companies 0 1,741
Increase in marketable securities 0 (18,733)
Decrease in marketable securities 10,268 35,386
Capital expenditures 0 (73)
Net cash provided by (used in) investing activities (1,912) 39,593
Cash Flows from Financing Activities:    
Proceeds from credit facility 50,000 0
Issuance costs of credit facility (5,696) 0
Repurchase of convertible senior debentures (14,455) 0
Issuance of Company common stock, net 12 5
Tax withholdings related to equity-based awards (175) (437)
Repurchase of Company common stock 0 (5,389)
Net cash provided by (used in) financing activities 29,686 (5,821)
Net change in cash, cash equivalents and restricted cash equivalents 12,259 19,658
Cash, cash equivalents and restricted cash equivalents at beginning of period 28,394 32,838
Cash, cash equivalents and restricted cash equivalents at end of period $ 40,653 $ 52,496
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY - 9 months ended Sep. 30, 2017 - USD ($)
shares in Thousands, $ in Thousands
Total
Accumulated Deficit
AOCI Attributable to Parent
Common Stock
Additional Paid-in Capital
Treasury Stock
Balance at Dec. 31, 2016 $ 169,777 $ (626,904) $ (431) $ 2,157 $ 816,016 $ (21,061)
Balance (in shares) at Dec. 31, 2016       21,573    
Balance (in shares) at Dec. 31, 2016           1,209
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (69,844) (69,844)        
Stock options exercised, net of tax withholdings 12       (48) $ 60
Stock options exercised, net of tax withholdings (in shares)           (4)
Issuance of restricted stock, net of tax withholdings (40)       (917) $ 877
Issuance of restricted stock, net of tax withholdings (in shares)           (44)
Stock-based compensation expense 806       806  
Repurchase of convertible senior debentures (826)       (826)  
Other comprehensive income 327   327      
Balance at Sep. 30, 2017 $ 100,212 $ (696,748) $ (104) $ 2,157 $ 815,031 $ (20,124)
Balance (in shares) at Sep. 30, 2017       21,573    
Balance (in shares) at Sep. 30, 2017           1,161
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statement - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Statement of Comprehensive Income [Abstract]        
Net loss $ (18,650) $ (24,085) $ (69,844) $ (561)
Share of other comprehensive income of equity method investments 274 3 277 13
Reclassification adjustment for sale of equity method investments 0 0 50 0
Total comprehensive loss $ (18,376) $ (24,082) $ (69,517) $ (548)
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
General
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
General
General
The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2016 Annual Report on Form 10-K.
Liquidity
As of September 30, 2017, the Company had $34.3 million of cash and cash equivalents and $5.4 million of marketable securities for a total of $39.7 million. As of September 30, 2017, the Company had $41.0 million of principal outstanding on its convertible senior notes, which the Company anticipates repaying or refinancing by the maturity date of May 15, 2018.
In May 2017, the Company entered into a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). As of September 30, 2017, the Company had $50.0 million of principal outstanding on the Credit Facility due in May 2020. The Credit Facility requires the Company to maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash, of at least 1.75x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of the Company’s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold, of at least $350 million; and (iv) certain diversification requirements and concentration limits with respect to the Company’s capital deployments to its partner companies. As of the date these consolidated financial statements were issued, the Company was in compliance with all of these covenants.
The Company funds its operations with cash and marketable securities on hand as well as proceeds from the sales of its interest in its partner companies. Due to the nature of the mergers and acquisitions market, and the developmental cycle of companies like the Company’s partner companies, the Company’s ability to generate specific amounts of liquidity from sales of its partner company interests in any given period of time cannot be assured. Accordingly, the forecasts which the Company utilizes for projecting future compliance with covenants related to its Credit Facility include significantly discounted probability-weighted proceeds from the sales of its interests in its partner companies. Based on these forecasts, management believes the Company will continue to remain in compliance with all of its debt covenants. Management's plans to remain in compliance with these covenants include selling certain of its partner company interests in the ordinary course of its business and limiting capital deployments to new and existing partner companies.
Non-compliance with any of the covenants would constitute an event of default under the Credit Facility, and the Lender could choose to accelerate the maturity of the indebtedness. If the Lender were to accelerate the maturity of the indebtedness, the Company may not have sufficient immediate liquidity to repay the entire balance of its outstanding borrowings and other obligations under the Credit Facility. Should the Company not be in compliance with any of its debt covenants and be unable to obtain waivers for such events of default, management would pursue one of a number of potential alternatives to satisfy the obligations, including completing an equity offering or obtaining a new debt facility to refinance its existing debt.
Significant Accounting Policies
Restricted Cash Equivalents
Restricted cash equivalents consist of certificates of deposit with various maturity dates. Amounts included in restricted cash equivalents represent those required to be set aside by a contractual agreement with a bank as collateral for a letter of credit. The restriction on the cash will lapse when the related letter of credit is terminated or expires. The letter of credit is scheduled to expire on March 31, 2019. The following table provides a reconciliation of cash, cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:
 
September 30, 2017
 
December 31, 2016
 
(Unaudited - In thousands)
Cash and cash equivalents
$
34,317

 
$
22,058

Long-term restricted cash equivalents
6,336

 
6,336

Total cash, cash equivalents and restricted cash equivalents
$
40,653

 
$
28,394



Recent Accounting Pronouncements
Evaluation of Accounting Standards Update No. 2014-09
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 and related subsequent amendments outline a single comprehensive model to use to account for revenue arising from contracts with customers and supersede most current revenue recognition guidance. For public companies, the guidance is effective for annual periods beginning after December 15, 2017 and any interim periods that fall within that reporting period. For nonpublic companies, the guidance is effective for annual periods beginning after December 15, 2018 and interim periods within annual periods beginning after December 15, 2019 with early adoption permitted. As the new standard will supersede most existing revenue guidance, it could impact revenue and cost recognition for partner companies. Any change in revenue or cost recognition for partner companies could affect the Company's recognition of its share of the results of its equity method partner companies. The Company has been closely monitoring the FASB and SEC activity related to the new standard.  On July 20, 2017, the SEC staff observer at the FASB’s Emerging Issues Task Force ("EITF") meeting announced that the SEC staff will not object if a private company equity method investee meeting the definition of a public business entity that otherwise would not meet the definition of a public business entity except for the inclusion of its financial statements or financial information in another entity’s filings with the SEC, uses private company adoption dates for the new revenue standard.  As a result, the Company anticipates that its private, calendar year partner companies will adopt the new revenue standard for the year ending December 31, 2019.  The impact of adoption of the new revenue standard will be reflected in the Company’s financial results for the interim and annual reporting periods beginning in 2020 on a one quarter-lag basis.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Ownership Interests in and Advances to Partner Companies and Funds
 9 Months Ended
Sep. 30, 2017
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]  
Ownership Interests in and Advances to Partner Companies
Ownership Interests in and Advances to Partner Companies
The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies.   
   
September 30, 2017
 
December 31, 2016
   
(Unaudited - In thousands)
Equity Method:
   
 
 
Partner companies
$
113,869

 
$
154,219

Private equity funds
444

 
447

   
114,313

 
154,666

Cost Method:
   
 
 
Other holdings
2,762

 
2,112

Private equity funds
1,334

 
1,550

   
4,096

 
3,662

Advances to partner companies
20,289

 
25,142

   
$
138,698

 
$
183,470


In August 2017, Good Start Genetics, Inc. was acquired by Invitae Corporation ("Invitae"). The Company received 414,237 shares of Invitae common stock worth $4.3 million on the closing date in connection with the transaction, excluding 137,125 shares of Invitae common stock worth $1.4 million on the closing date which will be held in escrow until August 2018. The Company recognized a gain of $4.3 million on the transaction, which is included in Equity income (loss) in the Consolidated Statements of Operations for the three and nine months ended September 30, 2017. The Invitae shares are classified as Trading securities and recorded at fair value on the Consolidated Balance Sheet at September 30, 2017.
In March 2017, the Company sold its interest in partner company Nexxt, Inc., formerly Beyond.com, back to Nexxt, Inc. for $26.0 million. The Company received $15.5 million in cash and a three-year, $10.5 million note for the balance due, which accrues interest at a rate of 9.5% per annum. The receipt of the $15.5 million in cash resulted in a gain of $0.1 million which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The $10.5 million note is fully reserved and has a carrying value of zero as of September 30, 2017. A gain will be recorded when the note is repaid. Interest is payable annually and interest income is recorded as earned throughout the year.
In the second quarter of 2017, the Company recognized an impairment charge of $3.6 million related to Spongecell, Inc. which is reflected in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The impairment was based on the value at which the Company expects Spongecell to raise its next financing round.
In the first and second quarters of 2017, the Company recognized impairment charges of $2.7 million and $2.2 million, respectively, related to Pneuron, Inc. which is reflected in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017. The impairments were due to a decline in revenue and an inability to attract third party investors or acquirers. Pneuron has ceased business operations and the adjusted carrying value of the Company's interest in Pneuron is $0.0 million at September 30, 2017.
In April 2016, Putney, Inc. was acquired by Dechra Pharmaceuticals Plc. The Company received $58.6 million in cash proceeds in connection with the transaction. In April 2017, the Company received an additional $0.7 million in connection with the expiration of the final escrow period resulting in a gain of $0.7 million which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.
In July 2015, Quantia, Inc. was acquired by Physicians Interactive. The Company received $7.8 million in initial cash proceeds in connection with the transaction in July 2015 and $0.6 million in connection with the expiration of the initial escrow period in July 2016. In January 2017, the Company received an additional $0.6 million in connection with the expiration of the final escrow period resulting in a gain of $0.6 million which is included in Equity income (loss) in the Consolidated Statements of Operations for the nine months ended September 30, 2017.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions of Ownership Interests in Partner Companies and Funds
 9 Months Ended
Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]  
Acquisitions of Ownership Interests in Partner Companies
Acquisitions of Ownership Interests in Partner Companies
In September, August, March and February 2017, the Company funded an aggregate of $4.9 million of convertible bridge loans to InfoBionic, Inc. The Company had previously deployed an aggregate of $14.5 million in InfoBionic. InfoBionic is an emerging digital health company focused on creating patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. The Company accounts for its interest in InfoBionic under the equity method.
In September, July and June 2017, the Company funded an aggregate of $1.6 million of convertible bridge loans to Cask Data, Inc. The Company had previously deployed an aggregate of $11.0 million in Cask Data. Cask Data makes building and running big data solutions on-premises or in the cloud easy with Cask Data Application Platform. The Company accounts for its interest in Cask Data under the equity method.
In September 2017, the Company deployed $2.5 million into meQuilibrium. The Company had previously deployed an aggregate of $8.0 million in meQuilibrium. meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being. The Company accounts for its interest in meQuilibrium under the equity method.
In August 2017, the Company funded $0.3 million of convertible bridge loans to Hoopla Software, Inc. The Company had previously deployed an aggregate of $4.8 million in Hoopla Software. Hoopla Software provides cloud-based software that helps sales organizations inspire and motivate sales team performance. The Company accounts for its interest in Hoopla Software under the equity method.
In August, June and February 2017, the Company funded an aggregate of $1.5 million of convertible loans to NovaSom, Inc. The Company had previously deployed an aggregate of $22.1 million in NovaSom. NovaSom is a medical device company focused on obstructive sleep apnea, specifically home testing with its FDA-cleared wireless device called AccuSom® home sleep test. The Company accounts for its interest in NovaSom under the equity method.
In July 2017, the Company deployed $1.8 million into QuanticMind, Inc. The Company had previously deployed an aggregate of $9.7 million in QuanticMind. QuanticMind delivers the most intelligent, scalable and fastest platform for maximizing digital marketing performance, including paid search and social, for enterprises. The Company accounts for its interest in QuanticMind under the equity method.
In June and April 2017, the Company funded an aggregate of $3.0 million of a convertible bridge loan to Sonobi, Inc. The Company had previously deployed $5.4 million in Sonobi. Sonobi is an advertising technology developer that designs advertising tools and solutions for the industry's leading media, publishers, brand advertisers, media agencies, DSPs, and media technology providers. The Company accounts for its interest in Sonobi under the equity method.
In June and January 2017, the Company funded an aggregate of $2.0 million of convertible bridge loans to WebLinc, Inc. The Company had previously deployed an aggregate of $12.0 million in WebLinc. WebLinc is a commerce platform and services provider for fast growing online retailers. The Company accounts for its interest in WebLinc under the equity method.
In June 2017, the Company funded $1.8 million of a convertible bridge loan to Good Start Genetics, Inc. The Company had previously deployed an aggregate of $17.2 million in Good Start Genetics. Good Start Genetics was acquired by Invitae Corporation in August 2017.
In May 2017, the Company deployed $2.1 million into Trice Medical, Inc. The Company had previously deployed an aggregate of $8.0 million in Trice Medical. Trice Medical is a diagnostics company focused on micro invasive technologies. The Company accounts for its interest in Trice Medical under the equity method.
In April 2017, the Company deployed $1.5 million into Aktana, Inc. The Company had previously deployed an aggregate of $8.2 million in Aktana. Aktana leverages big data and machine learning to enable pharmaceutical brands to dynamically optimize their strategy and enhance sales execution. The Company accounts for its interest in Aktana under the equity method.
In March and January 2017, the Company deployed an aggregate of $2.0 million into CloudMine, Inc. The Company had previously deployed an aggregate of $5.5 million in CloudMine. CloudMine empowers payers, providers, and pharmaceutical organizations to mobilize patient information by building robust applications and driving actionable insights. The Company accounts for its interest in CloudMine under the equity method.
In March 2017, the Company funded $0.2 million of a bridge loan to Lumesis, Inc. The Company had previously deployed an aggregate of $6.2 million in Lumesis. Lumesis is a financial technology company focused on providing business efficiency, regulatory and data solutions to the municipal bond marketplace. The Company accounts for its interest in Lumesis under the equity method.
In January 2017, the Company deployed $2.4 million into Full Measure Education, Inc. The Company had previously deployed an aggregate of $8.6 million in Full Measure. Full Measure designs next-generation, mobile-first technologies for colleges throughout the United States. The Company accounts for its interest in Full Measure under the equity method.
In January 2017, the Company funded $0.3 million of a convertible bridge loan to Aventura, Inc. to fund wind-down activities. The Company had previously deployed an aggregate of $6.2 million in Aventura. The adjusted carrying value of the Company's interest in Aventura was $0.0 million at September 30, 2017. The Company accounted for its interest in Aventura under the equity method.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial instruments recorded at fair value on the Company’s Consolidated Balance Sheets are categorized as follows:
Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Include other inputs that are directly or indirectly observable in the marketplace.
Level 3—Unobservable inputs which are supported by little or no market activity.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016:
   
Carrying
Value
 
Fair Value Measurement at September 30, 2017
   
Level 1
 
Level 2
 
Level 3
 
(Unaudited - In thousands)
Cash and cash equivalents
$
34,317

 
$
34,317

 
$
—

 
$
—

Long-term restricted cash equivalents

6,336

 
6,336

 
—

 
—

Trading securities
3,881

 
3,881

 
—

 
—

Marketable securities—held-to-maturity:
   
 
   
 
   
 
   
Certificates of deposit
$
5,420

 
$
5,420

 
$
—

 
$
—

 Total marketable securities
$
5,420

 
$
5,420

 
$
—

 
$
—

 
Carrying
Value
 
Fair Value Measurement at December 31, 2016
   
Level 1
 
Level 2
 
Level 3
 
(Unaudited - In thousands)
Cash and cash equivalents
$
22,058

 
$
22,058

 
$
—

 
$
—

Long-term restricted cash equivalents
6,336

 
6,336

 
—

 
—

Marketable securities—held-to-maturity:
   
 
 
 
 
 
 
Certificates of deposit
$
15,686

 
$
15,686

 
$
—

 
$
—

 Total marketable securities
$
15,686

 
$
15,686

 
$
—

 
$
—


As of September 30, 2017, $5.2 million of marketable securities had contractual maturities which were less than one year and $0.2 million of marketable securities had contractual maturities greater than one year. Certificates of deposit are classified as held-to-maturity securities carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1 inputs under the fair value hierarchy. Trading securities consist of 414,237 shares of Invitae Corporation common shares obtained in connection with the sale of Good Start Genetics. The trading securities are carried at fair value based on the closing stock price on the last trading day of the reporting period.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Credit Facility and Convertible Debentures
 9 Months Ended
Sep. 30, 2017
Debt Disclosure [Abstract]  
Credit Facility and Convertible Debentures
Convertible Debentures
Credit Facility
In May 2017, the Company entered into a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). At closing, the Company borrowed $50.0 million, which resulted in net proceeds of $44.3 million after closing fees to the Lender and other third parties. The Credit Facility has a three-year term with a scheduled maturity of May 11, 2020 and bears interest at a rate of either: (A) LIBOR plus 8.5% (subject to a LIBOR floor of 1%), payable on the last day of the one, two or three month interest period applicable to the LIBOR rate advance, or (B) 7.5% plus the greater of: 2%; the Federal Funds Rate plus 0.5%; LIBOR plus 1%; or the U.S. Prime Rate, payable monthly in arrears. The Credit Facility is not amortized and interest payable under the Credit Facility will reflect at least $50 million as being drawn and outstanding at all times during the term. The Credit Facility also includes an unused line fee equal to 0.75% per annum of the average unused portion of the Credit Facility and a loan service fee, both paid quarterly. The Credit Facility is secured by all of the Company's assets in accordance with the terms of the Credit Facility.
The Credit Facility requires the Company to maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash of at least 1.75x the amount then outstanding under the Credit Facility; (iii) a minimum aggregate appraised value of the Company’s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold of at least $350 million; and (iv) certain diversification requirements and concentration limits with respect to the Company’s capital deployments to its partner companies. Subject to customary exclusions, the Lender has the right to have one observer representative attend meetings of the Company's Board of Directors.
The Credit Facility provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, nonpayment of principal or interest; non-compliance with debt covenants; defaults in, or failure to pay, certain other indebtedness; the rendering of judgments to pay certain amounts of money; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is not cured within the time periods specified (if any), the Lender may declare the outstanding amount under the Credit Facility to be immediately due and payable.
At September 30, 2017, the principal amount outstanding under the Credit Facility was $50.0 million, the unamortized discount and debt issuance costs were $5.1 million and the net carrying value of the credit facility was $44.9 million. The Company is amortizing the excess of the principal amount of the Credit Facility over its carrying value over the three-year term as additional interest expense using the effective interest method and recorded $0.4 million and $0.6 million of such expense for the three and nine months ended September 30, 2017. The effective interest rate on the Credit Facility is 14.5%.
Convertible Debentures
In November 2012, the Company issued $55.0 million principal amount of its 5.25% convertible senior debentures due on May 15, 2018 (the “2018 Debentures”). The 2018 Debentures may be settled in cash or partially in cash upon conversion. Accordingly, the Company separately accounts for the liability and equity components of the 2018 Debentures. The carrying amount of the liability component was determined at the transaction date by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component represented by the embedded conversion option was determined by deducting the fair value of the liability component from the initial proceeds of the 2018 Debentures as a whole.
In July and June 2017, the Company repurchased on the open market, and retired, an aggregate of $14.0 million face value of the 2018 Debentures at a cost of $14.5 million, including transaction fees. In connection with the repurchase of these 2018 Debentures, the Company recognized a $0.8 million reduction in equity which is included in Accumulated Paid-In Capital in the Consolidated Balance Sheet as of September 30, 2017 and a $29 thousand loss on extinguishment of the liability which is included in Other loss in the Consolidated Statements of Operations for the nine months ended September 30, 2017.
At September 30, 2017, the carrying amount of the equity component was $5.7 million, the principal amount of the liability component was $41.0 million, the unamortized discount and debt issuance costs were $0.9 million and the net carrying value of the liability component was $40.1 million. The Company is amortizing the excess of the face value of the 2018 Debentures over their carrying value over their term as additional interest expense using the effective interest method and recorded $0.4 million of such expense for the three months ended September 30, 2017 and 2016, and $1.6 million and $1.2 million for the nine months ended September 30, 2017 and 2016, respectively. The effective interest rate on the 2018 Debentures is 8.7%. At September 30, 2017, the fair value of the $41.0 million outstanding 2018 Debentures was approximately $42.2 million, based on the midpoint of the bid and ask prices as of such date. The Company anticipates repaying or refinancing the outstanding 2018 Debentures by the maturity date of May 15, 2018.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:   
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
 
(Unaudited - In thousands)
General and administrative expense
$
560

 
$
604

 
$
806

 
$
1,879

   
$
560

 
$
604

 
$
806

 
$
1,879


The fair value of the Company’s option awards to employees was estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate was based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected term of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility measured using weekly price observations of the Company’s common stock for a period equal to the stock option’s expected term.
At September 30, 2017, the Company had outstanding options that vest based on two different types of vesting schedules:
1)
performance-based;
2)
service-based.

Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company’s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. During the nine months ended September 30, 2017 and 2016, the Company did not issue any performance-based options to employees. During the nine months ended September 30, 2017 and 2016, 0 thousand and 4 thousand performance-based options vested, respectively. During the nine months ended September 30, 2017 and 2016, 8 thousand and 35 thousand performance-based options were canceled or forfeited. The Company recorded compensation expense related to performance-based options of $0.0 million for the three months ended September 30, 2017 and a reduction in compensation expense of $0.2 million for the nine months ended September 30, 2017. The Company recorded compensation expense related to performance-based options of $0.0 million and $0.2 million for the three and nine months ended September 30, 2016, respectively. The maximum number of unvested options at September 30, 2017 attainable under these grants was 284 thousand shares.
Service-based options generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based options is the period over which the award vests. During the nine months ended September 30, 2017 and 2016, the Company issued 0 thousand and 12 thousand service-based options, respectively, to employees. During the nine months ended September 30, 2017 and 2016, 78 thousand and 12 thousand service-based options, respectively, were canceled or forfeited. The Company recorded compensation expense related to service-based options of $0.0 million and $0.1 million for the three and nine months ended September 30, 2017, respectively. The Company recorded compensation expense related to service-based options of $0.1 million and $0.1 million for the three and nine months ended September 30, 2016, respectively.
Performance-based stock units vest based on achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies, as described above related to performance-based awards. Performance-based stock units represent the right to receive shares of the Company’s common stock, on a one-for-one basis. During the nine months ended September 30, 2017 and 2016, the Company did not issue any performance-based stock units to employees and no performance-based stock units vested. During the nine months ended September 30, 2017 and 2016, 6 thousand and 0 thousand performance-based stock units were canceled or forfeited. Under the terms of the 2016, 2015 and 2014 performance-based awards, once performance-based stock units are fully vested, participants are entitled to receive cash payments based on their initial performance grant values as target capital returns are exceeded. At September 30, 2017, the liability associated with such potential cash payments was $0.0 million.
During the nine months ended September 30, 2017 and 2016, the Company issued 50 thousand and 43 thousand deferred stock units, respectively, to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in lieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of employment or service, death or permanent disability.
During the nine months ended September 30, 2017 and 2016, the Company issued 7 thousand and 0 thousand restricted stock awards, respectively, and 3 thousand and 1 thousand restricted stock awards were canceled or forfeited, respectively.
Total compensation expense for performance-based stock units, deferred stock units, and restricted stock was $0.5 million and $0.5 million for the three months ended September 30, 2017 and 2016, respectively, and $1.0 million and $1.5 million for the nine months ended September 30, 2017 and 2016, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company’s consolidated income tax benefit (expense) was $0.0 million for the three and nine months ended September 30, 2017 and 2016. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in the three and nine months ended September 30, 2017 was offset by changes in the valuation allowance. The tax expense that would have been recognized in the three and nine months ended September 30, 2016 was offset by changes in the valuation allowance. During the nine months ended September 30, 2017, the Company had no material changes in uncertain tax positions.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income (Loss) Per Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share
Net Income (Loss) Per Share
The calculations of net income (loss) per share were as follows:
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
 
(Unaudited - In thousands, except per share data)
Basic:
   
 
   
 
   
 
   
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Weighted average common shares outstanding
20,455

 
20,387

 
20,416

 
20,390

Net loss per share
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
 
 
 
 
 
 
 
 
Diluted:
 
 
 
 
 
 
 
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Weighted average common shares outstanding
20,455

 
20,387

 
20,416

 
20,390

Net loss for dilutive share computation
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
 
 
 
 
 
 
 
 

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).
If a consolidated or equity method partner company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the partner company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.
Diluted earnings per share for the three and nine months ended September 30, 2017 and 2016 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:
•
At September 30, 2017 and 2016, options to purchase 0.6 million and 0.7 million shares of common stock, respectively, at prices ranging from $9.83 to $19.95 and $9.83 to $19.95, respectively, were excluded from the calculations.
•
At September 30, 2017 and 2016, unvested restricted stock, performance-based stock units and DSUs convertible into 0.9 million and 0.6 million shares of stock, respectively, were excluded from the calculations.
•
At September 30, 2017 and 2016, 2.3 million and 3.0 million shares of common stock representing the effect of the assumed conversion of the 2018 Debentures, were excluded from the calculations.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting
The Company operates as one operating segment based upon the similar nature of its technology-driven partner companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. As of September 30, 2017, the Company held interests in 26 non-consolidated partner companies. The Company’s active partner companies were as follows as of September 30, 2017:
Partner Company
Safeguard Primary Ownership as of September 30, 2017
 
Accounting Method
AdvantEdge Healthcare Solutions, Inc.
40.1%
 
Equity
Aktana, Inc.
24.5%
 
Equity
Apprenda, Inc.
29.4%
 
Equity
Brickwork
20.3%
 
Equity
Cask Data, Inc.
31.3%
 
Equity
CloudMine, Inc.
47.4%
 
Equity
Clutch Holdings, Inc.
42.7%
 
Equity
Full Measure Education, Inc.
42.3%
 
Equity
Hoopla Software, Inc.
25.5%
 
Equity
InfoBionic, Inc.
39.5%
 
Equity
Lumesis, Inc.
43.8%
 
Equity
MediaMath, Inc.
20.4%
 
Equity
meQuilibrium
37.0%
 
Equity
Moxe Health Corporation
32.4%
 
Equity
NovaSom, Inc.
31.7%
 
Equity
Prognos (fka Medivo, Inc.)
35.2%
 
Equity
Propeller Health, Inc.
24.0%
 
Equity
QuanticMind, Inc.
24.7%
 
Equity
Sonobi, Inc.
21.6%
 
Equity
Spongecell, Inc.
23.0%
 
Equity
Syapse, Inc.
26.0%
 
Equity
T-REX Group, Inc.
21.3%
 
Equity
Transactis, Inc.
23.8%
 
Equity
Trice Medical, Inc.
24.9%
 
Equity
WebLinc, Inc.
38.0%
 
Equity
Zipnosis, Inc.
25.4%
 
Equity

 As of September 30, 2017 and December 31, 2016, all of the Company’s assets were located in the United States.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
The Company and its partner companies are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its partner companies. The Company records costs associated with legal fees as such services are rendered.
The Company had outstanding guarantees of $3.8 million at September 30, 2017 which related to one of the Company's private equity holdings.
The Company is required to return a portion or all the distributions it received as a general partner of a private equity fund for further distribution to such fund's limited partners (“clawback”). The Company’s ownership in the fund is 19%. The clawback liability is joint and several, such that the Company may be required to fund the clawback for other general partners should they default. The Company believes its potential liability due to the possibility of default by other general partners is remote. The Company was notified by the fund's manager that the fund is being dissolved and $1.0 million of the Company's clawback liability was paid in the first quarter of 2017. The maximum additional clawback liability is $0.3 million which was reflected in Other long-term liabilities on the Consolidated Balance Sheet at September 30, 2017.
 
In October 2001, the Company entered into an agreement with a former Chairman and Chief Executive Officer of the Company, to provide for annual payments of $0.65 million per year and certain health care and other benefits for life. The related current liability of $0.8 million was included in Accrued expenses and other current liabilities and the long-term portion of $1.8 million was included in Other long-term liabilities on the Consolidated Balance Sheet at September 30, 2017.
The Company provided a $6.3 million letter of credit that is scheduled to expire on March 31, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters as required in connection with the sale of CompuCom Systems in 2004. The letter of credit is secured by cash which is classified as Long-term restricted cash equivalents on the Consolidated Balance Sheet.
The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under the agreements was approximately $3.0 million at September 30, 2017.
In June 2011, the Company's former partner company, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH recently entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Equity
Equity
In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the nine months ended September 30, 2016, the Company repurchased 0.4 million shares at an aggregate cost of $5.4 million with $14.6 million remaining for repurchase under the existing authorization.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
General General (Policies)
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Restricted Cash Equivalents
Restricted Cash Equivalents
Restricted cash equivalents consist of certificates of deposit with various maturity dates. Amounts included in restricted cash equivalents represent those required to be set aside by a contractual agreement with a bank as collateral for a letter of credit. The restriction on the cash will lapse when the related letter of credit is terminated or expires.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Evaluation of Accounting Standards Update No. 2014-09
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 and related subsequent amendments outline a single comprehensive model to use to account for revenue arising from contracts with customers and supersede most current revenue recognition guidance. For public companies, the guidance is effective for annual periods beginning after December 15, 2017 and any interim periods that fall within that reporting period. For nonpublic companies, the guidance is effective for annual periods beginning after December 15, 2018 and interim periods within annual periods beginning after December 15, 2019 with early adoption permitted. As the new standard will supersede most existing revenue guidance, it could impact revenue and cost recognition for partner companies. Any change in revenue or cost recognition for partner companies could affect the Company's recognition of its share of the results of its equity method partner companies. The Company has been closely monitoring the FASB and SEC activity related to the new standard.  On July 20, 2017, the SEC staff observer at the FASB’s Emerging Issues Task Force ("EITF") meeting announced that the SEC staff will not object if a private company equity method investee meeting the definition of a public business entity that otherwise would not meet the definition of a public business entity except for the inclusion of its financial statements or financial information in another entity’s filings with the SEC, uses private company adoption dates for the new revenue standard.  As a result, the Company anticipates that its private, calendar year partner companies will adopt the new revenue standard for the year ending December 31, 2019.  The impact of adoption of the new revenue standard will be reflected in the Company’s financial results for the interim and annual reporting periods beginning in 2020 on a one quarter-lag basis.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
General General (Tables)
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:
 
September 30, 2017
 
December 31, 2016
 
(Unaudited - In thousands)
Cash and cash equivalents
$
34,317

 
$
22,058

Long-term restricted cash equivalents
6,336

 
6,336

Total cash, cash equivalents and restricted cash equivalents
$
40,653

 
$
28,394
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Ownership Interests in and Advances to Partner Companies and Funds (Tables)
 9 Months Ended
Sep. 30, 2017
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]  
Ownership Interests in and Advances to Partner Companies and Private Equity Funds
The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies.   
   
September 30, 2017
 
December 31, 2016
   
(Unaudited - In thousands)
Equity Method:
   
 
 
Partner companies
$
113,869

 
$
154,219

Private equity funds
444

 
447

   
114,313

 
154,666

Cost Method:
   
 
 
Other holdings
2,762

 
2,112

Private equity funds
1,334

 
1,550

   
4,096

 
3,662

Advances to partner companies
20,289

 
25,142

   
$
138,698

 
$
183,470
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016:
   
Carrying
Value
 
Fair Value Measurement at September 30, 2017
   
Level 1
 
Level 2
 
Level 3
 
(Unaudited - In thousands)
Cash and cash equivalents
$
34,317

 
$
34,317

 
$
—

 
$
—

Long-term restricted cash equivalents

6,336

 
6,336

 
—

 
—

Trading securities
3,881

 
3,881

 
—

 
—

Marketable securities—held-to-maturity:
   
 
   
 
   
 
   
Certificates of deposit
$
5,420

 
$
5,420

 
$
—

 
$
—

 Total marketable securities
$
5,420

 
$
5,420

 
$
—

 
$
—

 
Carrying
Value
 
Fair Value Measurement at December 31, 2016
   
Level 1
 
Level 2
 
Level 3
 
(Unaudited - In thousands)
Cash and cash equivalents
$
22,058

 
$
22,058

 
$
—

 
$
—

Long-term restricted cash equivalents
6,336

 
6,336

 
—

 
—

Marketable securities—held-to-maturity:
   
 
 
 
 
 
 
Certificates of deposit
$
15,686

 
$
15,686

 
$
—

 
$
—

 Total marketable securities
$
15,686

 
$
15,686

 
$
—

 
$
—
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation Expense
Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:   
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
 
(Unaudited - In thousands)
General and administrative expense
$
560

 
$
604

 
$
806

 
$
1,879

   
$
560

 
$
604

 
$
806

 
$
1,879
Types of Vesting Schedules
At September 30, 2017, the Company had outstanding options that vest based on two different types of vesting schedules:
1)
performance-based;
2)
service-based.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Calculations of Net Loss Per Share
The calculations of net income (loss) per share were as follows:
   
Three months ended September 30,
 
Nine months ended September 30,
   
2017
 
2016
 
2017
 
2016
 
(Unaudited - In thousands, except per share data)
Basic:
   
 
   
 
   
 
   
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Weighted average common shares outstanding
20,455

 
20,387

 
20,416

 
20,390

Net loss per share
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
 
 
 
 
 
 
 
 
Diluted:
 
 
 
 
 
 
 
Net loss
$
(18,650
)
 
$
(24,085
)
 
$
(69,844
)
 
$
(561
)
Weighted average common shares outstanding
20,455

 
20,387

 
20,416

 
20,390

Net loss for dilutive share computation
$
(0.91
)
 
$
(1.18
)
 
$
(3.42
)
 
$
(0.03
)
 
 
 
 
 
 
 
 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Active Partner Companies by Segment
The Company’s active partner companies were as follows as of September 30, 2017:
Partner Company
Safeguard Primary Ownership as of September 30, 2017
 
Accounting Method
AdvantEdge Healthcare Solutions, Inc.
40.1%
 
Equity
Aktana, Inc.
24.5%
 
Equity
Apprenda, Inc.
29.4%
 
Equity
Brickwork
20.3%
 
Equity
Cask Data, Inc.
31.3%
 
Equity
CloudMine, Inc.
47.4%
 
Equity
Clutch Holdings, Inc.
42.7%
 
Equity
Full Measure Education, Inc.
42.3%
 
Equity
Hoopla Software, Inc.
25.5%
 
Equity
InfoBionic, Inc.
39.5%
 
Equity
Lumesis, Inc.
43.8%
 
Equity
MediaMath, Inc.
20.4%
 
Equity
meQuilibrium
37.0%
 
Equity
Moxe Health Corporation
32.4%
 
Equity
NovaSom, Inc.
31.7%
 
Equity
Prognos (fka Medivo, Inc.)
35.2%
 
Equity
Propeller Health, Inc.
24.0%
 
Equity
QuanticMind, Inc.
24.7%
 
Equity
Sonobi, Inc.
21.6%
 
Equity
Spongecell, Inc.
23.0%
 
Equity
Syapse, Inc.
26.0%
 
Equity
T-REX Group, Inc.
21.3%
 
Equity
Transactis, Inc.
23.8%
 
Equity
Trice Medical, Inc.
24.9%
 
Equity
WebLinc, Inc.
38.0%
 
Equity
Zipnosis, Inc.
25.4%
 
Equity
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
General Significant Accounting Policies (Details)
Sep. 30, 2017
USD ($)
May 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Debt Instrument [Line Items]          
Cash and cash equivalents $ 34,317,000   $ 22,058,000    
Marketable securities 5,400,000        
Cash, cash equivalents, and marketable securities 39,700,000        
Cash and cash equivalents 34,317,000   22,058,000    
Long-term restricted cash equivalents 6,336,000   6,336,000    
Total cash, cash equivalents and restricted cash equivalents 40,653,000   $ 28,394,000 $ 52,496,000 $ 32,838,000
Convertible Debt          
Debt Instrument [Line Items]          
Principal amount outstanding 41,000,000        
Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Maximum borrowing capacity   $ 75,000,000      
Debt instrument, face amount $ 50,000,000        
Liquidity threshold   $ 20,000,000      
Unrestricted cash multiplier   1.75      
Minimum aggregate appraised value plus liquidity threshold   $ 350,000,000      
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Ownership Interests in and Advances to Partner Companies and Funds - Carrying Value (Detail) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Investments In And Advances To Affiliates [Line Items]    
Equity method investments $ 114,313 $ 154,666
Cost method investments 4,096 3,662
Advances to partner companies 20,289 25,142
Investments in and advance to affiliates, subsidiaries, associates, and joint ventures 138,698 183,470
Partner companies    
Investments In And Advances To Affiliates [Line Items]    
Equity method investments 113,869 154,219
Cost method investments 2,762 2,112
Private equity funds    
Investments In And Advances To Affiliates [Line Items]    
Equity method investments 444 447
Cost method investments $ 1,334 $ 1,550
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Ownership Interests in and Advances to Partner Companies and Funds - Narrative (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Aug. 31, 2017
Apr. 30, 2017
Mar. 31, 2017
Jan. 31, 2017
Jul. 31, 2016
Apr. 30, 2016
Jul. 31, 2015
Jun. 30, 2017
Mar. 31, 2017
Jun. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Mar. 03, 2017
Dec. 31, 2016
Investment [Line Items]                            
Proceeds from sale of business                     $ 16,604 $ 73,854    
Equity method investments                     114,313     $ 154,666
Good Start Genetics, Inc.                            
Investment [Line Items]                            
Number of shares received (in shares) 414,237                          
Amount of consideration received $ 4,300                          
Number of shares received, amount held in escrow (in shares) 137,125                          
Amount of consideration received, amount held in escrow $ 1,400                          
Gain on sale of business                     4,300      
Pneuron                            
Investment [Line Items]                            
Asset impairment charges               $ 2,200 $ 2,700          
Equity method investments                     0      
Putney Inc                            
Investment [Line Items]                            
Proceeds from sale of business   $ 700       $ 58,600                
Gain on sale of business                   $ 700        
Beyond.com, Inc                            
Investment [Line Items]                            
Amount of consideration received     $ 10,500                      
Consideration received per transaction     26,000                      
Proceeds from sale of business     $ 15,500                      
Term of note receivable (in years)     3 years                      
Interest rate on note receivable                         9.50%  
Gain on sale of business                     100      
Quantia, Inc.                            
Investment [Line Items]                            
Proceeds from sale of business       $ 600 $ 600   $ 7,800              
Gain on sale of business                     $ 600      
Spongecell Inc.                            
Investment [Line Items]                            
Asset impairment charges               $ 3,600            
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions of Ownership Interests in Partner Companies and Funds (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Jun. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments         $ 11,851 $ 34,841  
Equity method investments $ 114,313       114,313   $ 154,666
InfoBionic              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             14,500
Convertible bridge loan         4,900    
Cask Data              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             11,000
Convertible bridge loan         1,600    
meQuilibrium              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments 2,500           8,000
Hoopla Software, Inc.              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             4,800
Convertible bridge loan 300            
Novasom, Inc.              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             22,100
Convertible bridge loan         1,500    
QuanticMind              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments 1,800           9,700
Sonobi              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             5,400
Convertible bridge loan   $ 3,000          
WebLinc              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             12,000
Convertible bridge loan       $ 2,000      
Good Start Genetics, Inc.              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             17,200
Convertible bridge loan   1,800          
Trice Medical, Inc.              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments   2,100         8,000
Aktana, Inc.              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments   $ 1,500         8,200
CloudMine              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments     $ 2,000       5,500
Lumesis, Inc.              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             6,200
Convertible bridge loan     200        
Full Measure              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments     2,400       8,600
Aventura              
Schedule of Equity Method Investments [Line Items]              
Payments to acquire equity method investments             $ 6,200
Equity method investments $ 0       $ 0    
Convertible bridge loan     $ 300        
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term restricted cash equivalents $ 6,336,000 $ 6,336,000
Reported Value Measurement [Member] | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 34,317,000 22,058,000
Long-term restricted cash equivalents 6,336,000 6,336,000
Trading securities 3,881  
Total marketable securities 5,420,000 15,686,000
Reported Value Measurement [Member] | Fair Value, Measurements, Recurring | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total marketable securities 5,420,000 15,686,000
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 34,317,000 22,058,000
Long-term restricted cash equivalents 6,336,000 6,336,000
Trading securities 3,881  
Total marketable securities 5,420,000 15,686,000
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Long-term restricted cash equivalents 0 0
Trading securities 0  
Total marketable securities 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Long-term restricted cash equivalents 0 0
Trading securities 0  
Total marketable securities 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring | Certificates of deposit | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total marketable securities 5,420,000 15,686,000
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring | Certificates of deposit | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total marketable securities 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring | Certificates of deposit | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total marketable securities $ 0 $ 0
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Narrative (Detail) - USD ($)
$ in Thousands
 1 Months Ended
Aug. 31, 2017
Sep. 30, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Marketable securities, current   $ 5,171 $ 8,384
Marketable securities, non current   $ 249 $ 7,302
Good Start Genetics, Inc.      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of shares received (in shares) 414,237    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Credit Facility and Convertible Debentures - Credit Arrangements Narrative (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
Debt Instrument [Line Items]          
Proceeds from credit facility     $ 50,000,000 $ 0  
Revolving Credit Facility | Line of Credit          
Debt Instrument [Line Items]          
Maximum borrowing capacity $ 75,000,000        
Long-term line of credit outstanding         $ 50,000,000
Proceeds from credit facility $ 44,300,000        
Debt instrument, term (in years) 3 years        
Interest payable amount outstanding threshold $ 50,000,000        
Commitment fee percentage 0.75%        
Liquidity threshold $ 20,000,000        
Unrestricted cash multiplier 1.75        
Minimum aggregate appraised value plus liquidity threshold $ 350,000,000        
Long-term debt, gross   $ 50,000,000 50,000,000    
Unamortized discount and debt issuance costs   5,100,000 5,100,000    
Long-term debt   44,900,000 44,900,000    
Amortization of debt issuance costs   $ 400,000 $ 600,000    
Debt instrument, interest rate, effective percentage   14.50% 14.50%    
Revolving Credit Facility | Line of Credit | Interest Rate Application B          
Debt Instrument [Line Items]          
Basis spread on variable rate 2.00%        
Revolving Credit Facility | Line of Credit | Interest Rate Application B | Minimum          
Debt Instrument [Line Items]          
Basis spread on variable rate 7.50%        
Revolving Credit Facility | Line of Credit | London Interbank Offered Rate (LIBOR) | Interest Rate Application A          
Debt Instrument [Line Items]          
Basis spread on variable rate 8.50%        
Revolving Credit Facility | Line of Credit | London Interbank Offered Rate (LIBOR) | Interest Rate Application A | Minimum          
Debt Instrument [Line Items]          
Basis spread on variable rate 1.00%        
Revolving Credit Facility | Line of Credit | London Interbank Offered Rate (LIBOR) | Interest Rate Application B          
Debt Instrument [Line Items]          
Basis spread on variable rate 1.00%        
Revolving Credit Facility | Line of Credit | Federal Funds Effective Swap Rate | Interest Rate Application B          
Debt Instrument [Line Items]          
Basis spread on variable rate 0.50%        
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Credit Facility and Convertible Debentures - Convertible Senior Debentures Narrative (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Nov. 30, 2012
Debt Instrument [Line Items]            
Repurchase of convertible senior debentures     $ 826,000      
Convertible senior debentures - current $ 40,148,000   40,148,000   $ 0  
Additional Paid-in Capital            
Debt Instrument [Line Items]            
Repurchase of convertible senior debentures     826,000      
Convertible Debt            
Debt Instrument [Line Items]            
Aggregate face value of convertible senior debentures 41,000,000   41,000,000     $ 55,000,000.0
Interest rate on debentures           5.25%
Repurchased face amount 14,000,000   14,000,000      
Repayments of long-term debt     14,500,000      
Loss on extinguishment of debt     0      
Gross carrying amount of equity component 5,700,000   5,700,000      
Principal amount outstanding 41,000,000   41,000,000      
Deferred finance costs, noncurrent, net 900,000   900,000      
Convertible senior debentures - current 40,100,000   40,100,000      
Amortization of debt discount (premium) $ 400,000 $ 400,000 $ 1,600,000 $ 1,200,000    
Debt instrument, interest rate, effective percentage 8.70%   8.70%      
Fair value of debentures outstanding $ 42,200,000   $ 42,200,000      
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 560 $ 604 $ 806 $ 1,879
General And Administrative Expenses        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 560 $ 604 $ 806 $ 1,879
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation - Narrative (Detail)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
USD ($)
vesting_type
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
vesting_type
yr
shares
Sep. 30, 2016
USD ($)
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Number of award vesting types | vesting_type 2   2  
Cash liability for performance-based units | $ $ 0.0   $ 0.0  
Performance Shares        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Options vested (in shares)     0 4,000
Options, forfeitures in period (in shares)     8,000 35,000
Stock-based compensation expense | $ 0.0 $ 0.0 $ 0.2 $ 0.2
Stock-based compensation, maximum number of unvested shares (in shares)     284,000  
Cancelled in period (in shares)     6,000 0
Service Based Award        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Options, forfeitures in period (in shares)     78,000 12,000
Stock-based compensation expense | $ 0.0 0.1 $ 0.1 $ 0.1
Vesting period (in years)     4 years  
Expiration period (in years)     8 years  
Options issued (in shares)     0 12,000
Deferred Stock Units        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Percentage of shares vested in lieu of directors fees at the grant date     100.00%  
Portion of Director fees matched to deferred stock units     25.00%  
Vesting period of deferred stock (in years)     1 year  
Minimum age required for meeting directors fees deferred vest criteria | yr     65  
Deferred Stock Units | Director        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Shares issued to non-employee individual (in shares)     50,000 43,000
Restricted Stock        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Cancelled in period (in shares)     3,000 1,000
Restricted stock granted in period (in shares)     7,000 0
Deferred stock units, performance-based stock units and restricted stock        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock-based compensation expense | $ $ 0.5 $ 0.5 $ 1.0 $ 1.5
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Tax Disclosure [Abstract]        
Income tax benefit (expense) $ 0 $ 0 $ 0 $ 0
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Basic:        
Net income (loss) $ (18,650) $ (24,085) $ (69,844) $ (561)
Weighted average common shares outstanding (in shares) 20,455 20,387 20,416 20,390
Net income (loss) per share (in dollars per share) $ (0.91) $ (1.18) $ (3.42) $ (0.03)
Diluted:        
Weighted average common shares outstanding $ 20,455 $ 20,387 $ 20,416 $ 20,390
Net loss for dilutive share computation $ 0 $ 0 $ 0 $ 0
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income (Loss) Per Share - Narrative (Detail) - $ / shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2016
Stock Options      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Share of common stock excluded from diluted net loss per share calculation (in shares) 0.6 0.7  
Shares of common stock at prices ranging, lower limit (in dollars per share) $ 9.83 $ 9.83  
Shares of common stock at prices ranging, upper limit (in dollars per share) $ 19.95 $ 19.95  
Deferred stock units, performance-based stock units and restricted stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Share of common stock excluded from diluted net loss per share calculation (in shares) 0.9 0.6  
Convertible Senior Debentures due 2018      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Share of common stock excluded from diluted net loss per share calculation (in shares) 2.3   3.0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting - Narrative (Detail)
 9 Months Ended
Sep. 30, 2017
nonconsolidated_partner_company
segment
Segment Reporting [Abstract]  
Number of operating segments | segment 1
Non-consolidated partner companies | nonconsolidated_partner_company 26
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting - Active Partner Companies by Segment (Detail)
Sep. 30, 2017
AdvantEdge Healthcare Solutions, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 40.10%
Apprenda  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 29.40%
BrickWork  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 20.30%
Cask Data  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 31.30%
CloudMine  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 47.40%
Clutch Holdings, LLC  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 42.70%
Full Measure  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 42.30%
Hoopla Software, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 25.50%
Lumesis, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 43.80%
MediaMath, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 20.40%
Moxe Health  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 32.40%
Prognos  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 35.20%
QuanticMind, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 24.70%
Sonobi  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 21.60%
Spongecell  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 23.00%
T-REX Group, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 21.30%
Transactis  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 23.80%
WebLinc  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 38.00%
Healthcare | Aktana, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 24.50%
Healthcare | InfoBionic  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 39.50%
Healthcare | meQuilibrium  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 37.00%
Healthcare | Novasom, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 31.70%
Healthcare | Propeller  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 24.00%
Healthcare | Syapse, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 26.00%
Healthcare | Trice  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 24.90%
Healthcare | Zipnosis  
Schedule of Equity Method Investments [Line Items]  
Ownership interest under equity method, percentage 25.40%
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Detail) - USD ($)
$ in Thousands
 1 Months Ended
Oct. 31, 2001
Sep. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Commitment Contingencies And Guarantees [Line Items]        
Accrued expenses   $ 2,495   $ 2,223
Other long-term liabilities   3,504   $ 3,630
Annual payments $ 650      
Employee Severance        
Commitment Contingencies And Guarantees [Line Items]        
Maximum severance payments   3,000    
Letter of credit        
Commitment Contingencies And Guarantees [Line Items]        
Letter of credit under the credit facility   6,300    
Accrued expenses and other current liabilities        
Commitment Contingencies And Guarantees [Line Items]        
Liability to former chairman and chief executive officer, current   800    
Other long-term liabilities        
Commitment Contingencies And Guarantees [Line Items]        
Liability to former chairman and chief executive officer, non-current   1,800    
Clawback Liability        
Commitment Contingencies And Guarantees [Line Items]        
Other long-term liabilities   $ 300    
Company's ownership in the funds   19.00%    
Clawback Liability Paid     $ 1,000  
Private equity funds        
Commitment Contingencies And Guarantees [Line Items]        
Company outstanding guarantees   $ 3,800    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity (Details) - Common Stock - USD ($)
shares in Millions
 9 Months Ended
Sep. 30, 2016
Jul. 31, 2015
Equity, Class of Treasury Stock [Line Items]    
Stock repurchase program, authorized amount   $ 25,000,000.0
Repurchase of common stock (in shares) 0.4  
Stock repurchased during period, value $ 5,400,000  
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 14,600,000  
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 171 188 1 false 73 0 false 8 false false R1.htm 0002000 - Document - Document and Entity Information Sheet http://www.safeguard.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.safeguard.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.safeguard.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.safeguard.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.safeguard.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 1005000 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Sheet http://www.safeguard.com/role/ConsolidatedStatementOfChangesInEquity CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Statements 6 false false R7.htm 1006000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statement Sheet http://www.safeguard.com/role/ConsolidatedStatementsOfComprehensiveIncomeStatement CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statement Statements 7 false false R8.htm 2101100 - Disclosure - General Sheet http://www.safeguard.com/role/General General Notes 8 false false R9.htm 2102100 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds Sheet http://www.safeguard.com/role/OwnershipInterestsInAndAdvancesToPartnerCompaniesAndFunds Ownership Interests in and Advances to Partner Companies and Funds Notes 9 false false R10.htm 2105100 - Disclosure - Acquisitions of Ownership Interests in Partner Companies and Funds Sheet http://www.safeguard.com/role/AcquisitionsOfOwnershipInterestsInPartnerCompaniesAndFunds Acquisitions of Ownership Interests in Partner Companies and Funds Notes 10 false false R11.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.safeguard.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2108100 - Disclosure - Credit Facility and Convertible Debentures Sheet http://www.safeguard.com/role/CreditFacilityAndConvertibleDebentures Credit Facility and Convertible Debentures Notes 12 false false R13.htm 2110100 - Disclosure - Stock-Based Compensation Sheet http://www.safeguard.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2111100 - Disclosure - Income Taxes Sheet http://www.safeguard.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 2112100 - Disclosure - Net Income (Loss) Per Share Sheet http://www.safeguard.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 15 false false R16.htm 2115100 - Disclosure - Segment Reporting Sheet http://www.safeguard.com/role/SegmentReporting Segment Reporting Notes 16 false false R17.htm 2117100 - Disclosure - Commitments and Contingencies Sheet http://www.safeguard.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 2120100 - Disclosure - Equity Sheet http://www.safeguard.com/role/Equity Equity Notes 18 false false R19.htm 2201201 - Disclosure - General General (Policies) Sheet http://www.safeguard.com/role/GeneralGeneralPolicies General General (Policies) Policies 19 false false R20.htm 2301302 - Disclosure - General General (Tables) Sheet http://www.safeguard.com/role/GeneralGeneralTables General General (Tables) Tables 20 false false R21.htm 2302301 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds (Tables) Sheet http://www.safeguard.com/role/OwnershipInterestsInAndAdvancesToPartnerCompaniesAndFundsTables Ownership Interests in and Advances to Partner Companies and Funds (Tables) Tables http://www.safeguard.com/role/OwnershipInterestsInAndAdvancesToPartnerCompaniesAndFunds 21 false false R22.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.safeguard.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.safeguard.com/role/FairValueMeasurements 22 false false R23.htm 2310301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.safeguard.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.safeguard.com/role/StockBasedCompensation 23 false false R24.htm 2312301 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.safeguard.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.safeguard.com/role/NetIncomeLossPerShare 24 false false R25.htm 2315301 - Disclosure - Segment Reporting (Tables) Sheet http://www.safeguard.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.safeguard.com/role/SegmentReporting 25 false false R26.htm 2401403 - Disclosure - General Significant Accounting Policies (Details) Sheet http://www.safeguard.com/role/GeneralSignificantAccountingPoliciesDetails General Significant Accounting Policies (Details) Details 26 false false R27.htm 2402402 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds - Carrying Value (Detail) Sheet http://www.safeguard.com/role/OwnershipInterestsInAndAdvancesToPartnerCompaniesAndFundsCarryingValueDetail Ownership Interests in and Advances to Partner Companies and Funds - Carrying Value (Detail) Details 27 false false R28.htm 2402403 - Disclosure - Ownership Interests in and Advances to Partner Companies and Funds - Narrative (Detail) Sheet http://www.safeguard.com/role/OwnershipInterestsInAndAdvancesToPartnerCompaniesAndFundsNarrativeDetail Ownership Interests in and Advances to Partner Companies and Funds - Narrative (Detail) Details http://www.safeguard.com/role/OwnershipInterestsInAndAdvancesToPartnerCompaniesAndFundsTables 28 false false R29.htm 2405401 - Disclosure - Acquisitions of Ownership Interests in Partner Companies and Funds (Detail) Sheet http://www.safeguard.com/role/AcquisitionsOfOwnershipInterestsInPartnerCompaniesAndFundsDetail Acquisitions of Ownership Interests in Partner Companies and Funds (Detail) Details http://www.safeguard.com/role/AcquisitionsOfOwnershipInterestsInPartnerCompaniesAndFunds 29 false false R30.htm 2406402 - Disclosure - Fair Value Measurements - Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.safeguard.com/role/FairValueMeasurementsCarryingValueAndFairValueOfCertainFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements - Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 30 false false R31.htm 2406403 - Disclosure - Fair Value Measurements - Narrative (Detail) Sheet http://www.safeguard.com/role/FairValueMeasurementsNarrativeDetail Fair Value Measurements - Narrative (Detail) Details 31 false false R32.htm 2408401 - Disclosure - Credit Facility and Convertible Debentures - Credit Arrangements Narrative (Detail) Sheet http://www.safeguard.com/role/CreditFacilityAndConvertibleDebenturesCreditArrangementsNarrativeDetail Credit Facility and Convertible Debentures - Credit Arrangements Narrative (Detail) Details 32 false false R33.htm 2408402 - Disclosure - Credit Facility and Convertible Debentures - Convertible Senior Debentures Narrative (Detail) Sheet http://www.safeguard.com/role/CreditFacilityAndConvertibleDebenturesConvertibleSeniorDebenturesNarrativeDetail Credit Facility and Convertible Debentures - Convertible Senior Debentures Narrative (Detail) Details 33 false false R34.htm 2410402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Sheet http://www.safeguard.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Details 34 false false R35.htm 2410403 - Disclosure - Stock-Based Compensation - Narrative (Detail) Sheet http://www.safeguard.com/role/StockBasedCompensationNarrativeDetail Stock-Based Compensation - Narrative (Detail) Details 35 false false R36.htm 2411401 - Disclosure - Income Taxes (Detail) Sheet http://www.safeguard.com/role/IncomeTaxesDetail Income Taxes (Detail) Details http://www.safeguard.com/role/IncomeTaxes 36 false false R37.htm 2412402 - Disclosure - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Detail) Sheet http://www.safeguard.com/role/NetIncomeLossPerShareCalculationsOfNetIncomeLossPerShareDetail Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Detail) Details http://www.safeguard.com/role/NetIncomeLossPerShareTables 37 false false R38.htm 2412403 - Disclosure - Net Income (Loss) Per Share - Narrative (Detail) Sheet http://www.safeguard.com/role/NetIncomeLossPerShareNarrativeDetail Net Income (Loss) Per Share - Narrative (Detail) Details http://www.safeguard.com/role/NetIncomeLossPerShareTables 38 false false R39.htm 2415402 - Disclosure - Segment Reporting - Narrative (Detail) Sheet http://www.safeguard.com/role/SegmentReportingNarrativeDetail Segment Reporting - Narrative (Detail) Details 39 false false R40.htm 2415403 - Disclosure - Segment Reporting - Active Partner Companies by Segment (Detail) Sheet http://www.safeguard.com/role/SegmentReportingActivePartnerCompaniesBySegmentDetail Segment Reporting - Active Partner Companies by Segment (Detail) Details 40 false false R41.htm 2417401 - Disclosure - Commitments and Contingencies (Detail) Sheet http://www.safeguard.com/role/CommitmentsAndContingenciesDetail Commitments and Contingencies (Detail) Details http://www.safeguard.com/role/CommitmentsAndContingencies 41 false false R42.htm 2420401 - Disclosure - Equity (Details) Sheet http://www.safeguard.com/role/EquityDetails Equity (Details) Details http://www.safeguard.com/role/Equity 42 false false All Reports Book All Reports sfe-20170930.xml sfe-20170930.xsd sfe-20170930_cal.xml sfe-20170930_def.xml sfe-20170930_lab.xml sfe-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2016-01-31 true true ZIP 60 0000086115-17-000131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000086115-17-000131-xbrl.zip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end